CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | glycopeptide |
|
Accession: | CHEBI:24396
|
browse the term
|
Definition: | Any carbohydrate derivative that consists of glycan moieties covalently attached to the side chains of the amino acid residues that constitute the peptide. |
Synonyms: | exact_synonym: | glycopeptides |
| alt_id: | CHEBI:24395; CHEBI:5478 |
|
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions decreases expression |
EXP |
angiotensin I (1-7) inhibits the reaction [Bleomycin results in decreased expression of ACE protein] |
CTD |
PMID:20581171 |
|
NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
multiple interactions decreases expression |
EXP |
angiotensin I (1-7) inhibits the reaction [Bleomycin results in decreased expression of ACE2 mRNA] |
CTD |
PMID:20581171 |
|
NCBI chr X:32,050,734...32,095,860
Ensembl chr X:32,049,931...32,096,016
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
ISO EXP |
Bleomycin results in increased expression of ACTA2 mRNA; Bleomycin results in increased expression of ACTA2 protein allyl sulfide inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein]; andrographolide inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein]; montelukast inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein]; protocatechualdehyde inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein] 12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; 12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [Bleomycin results in increased expression of and results in increased phosphorylation of ACTA2 protein]; 2-((dimethylamino)methyl)-9-hydroxythieno(2,3-c)isoquinolin-5(4H)-one inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein]; [Arsenic Trioxide co-treated with Bleomycin] results in decreased expression of ACTA2 mRNA; [Bleomycin co-treated with Soot] results in increased expression of ACTA2 protein; Bleomycin results in increased expression of and results in increased phosphorylation of ACTA2 protein; Calcitriol inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein]; CCR2 gene mutant form inhibits the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; CEBPB protein affects the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of and results in increased phosphorylation of ACTA2 protein]; tripterine inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein]; Win 55212-2 inhibits the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; Win 55212-2 inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein] |
CTD |
PMID:14609568 PMID:17177178 PMID:21381050 PMID:23656969 PMID:24762191 PMID:25582705 PMID:25648892 PMID:26520185 PMID:27704718 PMID:28694203 PMID:31302203 PMID:31706003 PMID:31901889 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Actn1 |
actinin, alpha 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of ACTN1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 6:103,376,557...103,470,497
Ensembl chr 6:103,375,799...103,470,555
|
|
G |
Actn4 |
actinin alpha 4 |
decreases expression |
EXP |
Bleomycin results in decreased expression of ACTN4 protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:87,078,012...87,147,347
Ensembl chr 1:87,078,020...87,147,333
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
multiple interactions |
ISO |
Bleomycin results in increased expression of and results in increased activity of ADAM17 protein |
CTD |
PMID:22687607 |
|
NCBI chr 6:43,400,525...43,448,280
Ensembl chr 6:43,400,528...43,448,280
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
decreases expression |
EXP |
Bleomycin results in decreased expression of ADRA1B mRNA |
CTD |
PMID:15808516 |
|
NCBI chr10:29,392,762...29,450,644
Ensembl chr10:29,392,762...29,450,644
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions decreases expression |
EXP |
protocatechualdehyde inhibits the reaction [Bleomycin results in decreased expression of AGER protein] |
CTD |
PMID:25582705 PMID:25933445 |
|
NCBI chr20:4,363,152...4,366,079
Ensembl chr20:4,363,152...4,366,079
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions increases expression |
EXP |
angiotensin I (1-7) inhibits the reaction [Bleomycin results in increased expression of AGTR1 protein] |
CTD |
PMID:20581171 |
|
NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
|
|
G |
Ahsg |
alpha-2-HS-glycoprotein |
increases expression |
EXP |
Bleomycin results in increased expression of AHSG protein |
CTD |
PMID:25933445 |
|
NCBI chr11:81,711,269...81,717,594
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
ISO |
Bleomycin results in increased phosphorylation of AKT1 protein |
CTD |
PMID:22687607 PMID:26520185 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alb |
albumin |
increases expression |
EXP |
Bleomycin results in increased expression of ALB protein |
CTD |
PMID:25933445 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of ALDH1A1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ALDOC protein |
CTD |
PMID:29733421 |
|
NCBI chr10:65,586,504...65,590,093
Ensembl chr10:65,586,504...65,590,126
|
|
G |
Ankrd1 |
ankyrin repeat domain 1 |
increases expression |
ISO |
Bleomycin results in increased expression of ANKRD1 mRNA |
CTD |
PMID:26345256 |
|
NCBI chr 1:254,726,985...254,745,673
Ensembl chr 1:254,726,969...254,735,548
|
|
G |
Anp32e |
acidic nuclear phosphoprotein 32 family member E |
increases expression |
EXP |
Bleomycin results in increased expression of ANP32E protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:198,040,573...198,057,005
Ensembl chr 2:198,040,536...198,057,003
|
|
G |
Anxa2 |
annexin A2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of ANXA2 protein |
CTD |
PMID:25933445 |
|
NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
|
|
G |
Anxa3 |
annexin A3 |
decreases expression |
EXP |
Bleomycin results in decreased expression of ANXA3 protein |
CTD |
PMID:25933445 |
|
NCBI chr14:14,371,921...14,426,503
Ensembl chr14:14,364,008...14,426,437
|
|
G |
Anxa4 |
annexin A4 |
decreases expression |
EXP |
Bleomycin results in decreased expression of ANXA4 protein |
CTD |
PMID:25933445 |
|
NCBI chr 4:118,538,775...118,595,591
Ensembl chr 4:118,538,777...118,595,580
|
|
G |
Anxa5 |
annexin A5 |
increases expression |
EXP |
Bleomycin results in increased expression of ANXA5 protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:123,162,477...123,194,730
Ensembl chr 2:123,162,461...123,193,130
|
|
G |
Anxa6 |
annexin A6 |
decreases expression |
EXP |
Bleomycin results in decreased expression of ANXA6 protein |
CTD |
PMID:25933445 |
|
NCBI chr10:40,320,581...40,375,605
Ensembl chr10:40,320,581...40,375,605
|
|
G |
Anxa7 |
annexin A7 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ANXA7 protein |
CTD |
PMID:29733421 |
|
NCBI chr15:4,254,470...4,281,296
Ensembl chr15:4,254,499...4,281,287
|
|
G |
Aqp1 |
aquaporin 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of AQP1 mRNA |
CTD |
PMID:15782499 |
|
NCBI chr 4:85,551,503...85,563,683
Ensembl chr 4:85,551,502...85,569,360
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
Bleomycin results in increased expression of AREG mRNA |
CTD |
PMID:26817844 |
|
NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
|
|
G |
Arg1 |
arginase 1 |
increases expression |
ISO |
Bleomycin results in increased expression of ARG1 mRNA; Bleomycin results in increased expression of ARG1 protein |
CTD |
PMID:26345256 PMID:26526764 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases phosphorylation |
ISO |
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Bleomycin promotes the reaction [resveratrol results in increased phosphorylation of ATM protein]]; 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Bleomycin results in increased phosphorylation of ATM protein]; 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [resveratrol promotes the reaction [Bleomycin results in increased phosphorylation of ATM protein]]; Bleomycin promotes the reaction [resveratrol results in increased phosphorylation of ATM protein]; resveratrol promotes the reaction [Bleomycin results in increased phosphorylation of ATM protein] |
CTD |
PMID:24933654 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
decreases expression |
EXP |
Bleomycin results in decreased expression of ATP5F1B protein |
CTD |
PMID:25933445 |
|
NCBI chr 7:2,504,708...2,511,748
Ensembl chr 7:2,504,695...2,511,749
|
|
G |
Atp5if1 |
ATP synthase inhibitory factor subunit 1 |
increases expression |
EXP |
Bleomycin results in increased expression of ATPIF1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 5:150,719,570...150,723,287
Ensembl chr 5:150,719,569...150,723,321
|
|
G |
Atp5me |
ATP synthase membrane subunit e |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in increased expression of ATP5ME protein |
CTD |
PMID:29733421 |
|
NCBI chr14:2,325,308...2,326,436
Ensembl chr14:2,325,308...2,326,436
|
|
G |
Atp5po |
ATP synthase peripheral stalk subunit OSCP |
decreases expression |
ISO |
Bleomycin results in decreased expression of ATP5O protein |
CTD |
PMID:29733421 |
|
NCBI chr11:32,081,606...32,087,918
Ensembl chr11:32,081,574...32,088,002
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
multiple interactions decreases expression |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ATP6V1A protein Bleomycin results in decreased expression of ATP6V1A protein |
CTD |
PMID:29733421 |
|
NCBI chr11:61,531,386...61,584,634
Ensembl chr11:61,531,416...61,584,634
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
decreases expression |
EXP |
Bleomycin results in decreased expression of AVPR1A mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 7:67,341,366...67,345,290
Ensembl chr 7:67,341,080...67,345,308
|
|
G |
Basp1 |
brain abundant, membrane attached signal protein 1 |
increases expression |
EXP |
Bleomycin results in increased expression of BASP1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:77,586,424...77,632,626
Ensembl chr 2:77,586,424...77,632,628
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
allyl sulfide inhibits the reaction [Bleomycin results in increased expression of BAX protein]; Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of BAX mRNA]; Phytochemicals inhibits the reaction [Bleomycin results in increased expression of BAX mRNA] Bleomycin inhibits the reaction [Azacitidine results in increased expression of BAX mRNA] Bleomycin results in increased expression of BAX mRNA; Bleomycin results in increased expression of BAX protein |
CTD |
PMID:23656969 PMID:26093215 PMID:32278510 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression increases expression |
EXP ISO |
[Bleomycin co-treated with Bee Venoms] results in decreased expression of BCL2 mRNA; allyl sulfide promotes the reaction [Bleomycin results in increased expression of BCL2 protein]; Phytochemicals inhibits the reaction [Bleomycin results in decreased expression of BCL2 mRNA] Bleomycin inhibits the reaction [Azacitidine results in decreased expression of BCL2 mRNA]; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of BCL2 protein] [Polyphenols co-treated with Bleomycin] results in increased expression of BCL2 mRNA; [Tea co-treated with Bleomycin] results in increased expression of BCL2 mRNA |
CTD |
PMID:23656969 PMID:24822179 PMID:26093215 PMID:26800624 PMID:32278510 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl6b |
BCL6B, transcription repressor |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of BCL6B mRNA |
CTD |
PMID:29733421 |
|
NCBI chr10:56,834,363...56,840,058
Ensembl chr10:56,834,364...56,839,437
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases response to substance increases expression |
ISO EXP |
BIRC2 protein results in decreased susceptibility to Bleomycin Bleomycin results in increased expression of BIRC2 protein |
CTD |
PMID:10815900 PMID:15371238 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
ISO |
Bleomycin results in increased expression of BIRC5 mRNA |
CTD |
PMID:26345256 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Blmh |
bleomycin hydrolase |
affects response to substance |
ISO |
BLMH gene polymorphism affects the susceptibility to Bleomycin |
CTD |
PMID:12082022 |
|
NCBI chr10:63,197,367...63,240,447
Ensembl chr10:63,197,364...63,240,332
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
decreases expression |
ISO |
Bleomycin results in decreased expression of BMP7 mRNA |
CTD |
PMID:29408570 |
|
NCBI chr 3:170,879,972...170,955,820
Ensembl chr 3:170,879,973...170,955,399
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
ISO |
Bleomycin results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 1:225,035,956...225,046,137
Ensembl chr 1:225,037,737...225,046,040
|
|
G |
C1qb |
complement C1q B chain |
increases expression |
ISO |
Bleomycin results in increased expression of C1QB mRNA |
CTD |
PMID:26345256 |
|
NCBI chr 5:155,246,444...155,251,995
Ensembl chr 5:155,246,447...155,252,003
|
|
G |
Cald1 |
caldesmon 1 |
increases expression |
EXP |
Bleomycin results in increased expression of CALD1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 4:62,103,948...62,291,375
Ensembl chr 4:62,220,736...62,291,489
|
|
G |
Calml3 |
calmodulin-like 3 |
decreases expression |
EXP |
Bleomycin results in decreased expression of CALML3 protein |
CTD |
PMID:25933445 |
|
NCBI chr17:70,070,458...70,073,697
Ensembl chr17:70,072,156...70,073,530
|
|
G |
Calr |
calreticulin |
increases expression |
EXP |
Bleomycin results in increased expression of CALR protein |
CTD |
PMID:25933445 |
|
NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
|
|
G |
Calu |
calumenin |
increases expression |
EXP |
Bleomycin results in increased expression of CALU protein |
CTD |
PMID:25933445 |
|
NCBI chr 4:56,625,611...56,653,112
Ensembl chr 4:56,625,561...56,653,111
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of CA1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:88,185,204...88,227,486
Ensembl chr 2:88,217,188...88,227,479
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of CA2 protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
|
|
G |
Carhsp1 |
calcium regulated heat stable protein 1 |
increases expression |
EXP |
Bleomycin results in increased expression of CARHSP1 protein |
CTD |
PMID:25933445 |
|
NCBI chr10:7,041,510...7,055,107
Ensembl chr10:7,041,510...7,055,101
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity |
EXP ISO |
[Bleomycin co-treated with Bee Venoms] results in increased expression of CASP3 mRNA; allyl sulfide inhibits the reaction [Bleomycin results in increased expression of CASP3 protein]; Bleomycin results in increased cleavage of and results in increased activity of CASP3 protein; Phytochemicals inhibits the reaction [Bleomycin results in increased expression of CASP3 mRNA] [Polyphenols co-treated with Bleomycin] results in increased expression of CASP3 mRNA; [Tea co-treated with Bleomycin] results in increased expression of CASP3 mRNA Bleomycin results in increased expression of CASP3 mRNA; Bleomycin results in increased expression of CASP3 protein Bleomycin results in increased activity of CASP3 protein |
CTD |
PMID:15371238 PMID:22687607 PMID:23656969 PMID:24822179 PMID:26093215 PMID:26800624 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[Polyphenols co-treated with Bleomycin] results in increased expression of CASP8 mRNA; [Tea co-treated with Bleomycin] results in increased expression of CASP8 mRNA |
CTD |
PMID:26800624 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
EXP ISO |
Bleomycin results in increased cleavage of and results in increased activity of CASP9 protein [Polyphenols co-treated with Bleomycin] results in increased expression of CASP9 mRNA; [Tea co-treated with Bleomycin] results in increased expression of CASP9 mRNA Bleomycin results in increased activity of CASP9 protein |
CTD |
PMID:15371238 PMID:22687607 PMID:26800624 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cast |
calpastatin |
increases expression |
EXP |
Bleomycin results in increased expression of CAST protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:1,452,111...1,561,669
Ensembl chr 2:1,452,116...1,561,464
|
|
G |
Cat |
catalase |
increases response to substance decreases activity multiple interactions increases expression |
ISO EXP |
CAT protein results in increased susceptibility to Bleomycin Bleomycin results in decreased activity of CAT tripterine inhibits the reaction [Bleomycin results in decreased activity of CAT protein] IL1A protein promotes the reaction [Bleomycin results in increased expression of CAT protein]; IL1B protein promotes the reaction [Bleomycin results in increased expression of CAT protein]; TNF protein promotes the reaction [Bleomycin results in increased expression of CAT protein] Bleomycin results in decreased expression of and results in decreased activity of CAT protein; caffeic acid phenethyl ester inhibits the reaction [Bleomycin results in decreased expression of CAT protein]; Oils, Volatile inhibits the reaction [Bleomycin results in decreased activity of CAT protein] |
CTD |
PMID:8317554 PMID:10751631 PMID:23570914 PMID:26768587 PMID:28850077 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cav1 |
caveolin 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of CAV1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Cavin2 |
caveolae associated protein 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of CAVIN2 protein |
CTD |
PMID:25933445 |
|
NCBI chr 9:55,244,136...55,256,153
Ensembl chr 9:55,243,255...55,256,340
|
|
G |
Cckar |
cholecystokinin A receptor |
decreases expression |
EXP |
Bleomycin results in decreased expression of CCKAR mRNA |
CTD |
PMID:15808516 |
|
NCBI chr14:59,610,939...59,619,786
Ensembl chr14:59,611,434...59,619,783
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
increases expression decreases expression multiple interactions decreases response to substance |
ISO |
Bleomycin results in increased expression of CCL11 mRNA; Bleomycin results in increased expression of CCL11 protein Bleomycin results in decreased expression of CCL11 mRNA CCL11 protein promotes the reaction [Bleomycin results in increased expression of CCL2 mRNA]; CCL11 protein promotes the reaction [Bleomycin results in increased expression of TGFB1 mRNA] CCL11 gene mutant form results in decreased susceptibility to Bleomycin |
CTD |
PMID:16314464 PMID:29720568 |
|
NCBI chr10:69,434,965...69,439,566
Ensembl chr10:69,434,941...69,439,575
|
|
G |
Ccl12 |
chemokine (C-C motif) ligand 12 |
increases expression decreases expression multiple interactions |
ISO |
Bleomycin results in increased expression of CCL12 mRNA Bleomycin results in decreased expression of CCL12 mRNA [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; CCL12 protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]]; Dinoprostone inhibits the reaction [Bleomycin results in increased expression of CCL12 mRNA] |
CTD |
PMID:28434932 PMID:29720568 |
|
NCBI chr10:69,476,866...69,478,416
Ensembl chr10:69,476,775...69,478,462
|
|
G |
Ccl17 |
C-C motif chemokine ligand 17 |
increases expression |
ISO |
Bleomycin results in increased expression of CCL17 mRNA; Bleomycin results in increased expression of CCL17 protein |
CTD |
PMID:26345256 PMID:29175452 |
|
NCBI chr19:10,619,220...10,620,671
Ensembl chr19:10,619,220...10,620,671
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression decreases expression multiple interactions |
ISO |
Bleomycin results in increased expression of CCL2 mRNA; Bleomycin results in increased expression of CCL2 protein Bleomycin results in decreased expression of CCL2 mRNA Calcitriol inhibits the reaction [Bleomycin results in increased expression of CCL2 mRNA]; CCL11 protein promotes the reaction [Bleomycin results in increased expression of CCL2 mRNA]; CEBPB protein affects the reaction [Bleomycin results in increased expression of CCL2 mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Bleomycin results in increased expression of CCL2 mRNA]; Rosiglitazone inhibits the reaction [Bleomycin results in increased expression of CCL2 protein]; SPL-334 inhibits the reaction [Bleomycin results in increased expression of CCL2 protein]; tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of CCL2 mRNA]; tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of CCL2 protein] |
CTD |
PMID:15541506 PMID:16314464 PMID:17177178 PMID:19147827 PMID:26209236 PMID:26520185 PMID:26526764 PMID:29720568 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression decreases expression multiple interactions |
ISO |
Bleomycin results in increased expression of CCL3 mRNA Bleomycin results in decreased expression of CCL3 mRNA Calcitriol inhibits the reaction [Bleomycin results in increased expression of CCL3 mRNA] |
CTD |
PMID:26520185 PMID:29720568 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Bleomycin results in decreased expression of CCL4 mRNA |
CTD |
PMID:29720568 |
|
NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
|
|
G |
Ccl6 |
C-C motif chemokine ligand 6 |
increases expression |
ISO |
Bleomycin results in increased expression of CCL6 protein |
CTD |
PMID:29175452 |
|
NCBI chr10:70,798,118...70,802,750
Ensembl chr10:70,797,124...70,802,782
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
decreases expression |
ISO |
Bleomycin results in decreased expression of CCL7 mRNA |
CTD |
PMID:29720568 |
|
NCBI chr10:69,423,083...69,424,933
Ensembl chr10:69,423,086...69,424,979
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions increases expression |
ISO |
[CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 protein] Bleomycin results in increased expression of CCN2 mRNA; Bleomycin results in increased expression of CCN2 protein |
CTD |
PMID:19080365 PMID:26817844 PMID:28434932 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccng1 |
cyclin G1 |
increases expression |
ISO |
Bleomycin results in increased expression of CCNG1 mRNA |
CTD |
PMID:26345256 |
|
NCBI chr10:25,903,925...25,910,298
Ensembl chr10:25,903,911...25,910,325
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions increases expression decreases response to substance |
ISO |
CCR2 gene mutant form inhibits the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; CCR2 gene mutant form inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; CCR2 gene mutant form inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; CCR2 gene mutant form inhibits the reaction [Bleomycin results in increased expression of TNF mRNA] Bleomycin results in increased expression of CCR2 mRNA CCR2 gene mutant form results in decreased susceptibility to Bleomycin |
CTD |
PMID:14609568 PMID:29033951 |
|
|
|
G |
Ccr3 |
C-C motif chemokine receptor 3 |
increases expression |
ISO |
Bleomycin results in increased expression of CCR3 mRNA; Bleomycin results in increased expression of CCR3 protein |
CTD |
PMID:16314464 |
|
NCBI chr 8:133,026,539...133,040,999
Ensembl chr 8:133,029,625...133,040,997
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
affects expression |
ISO |
Bleomycin affects the expression of CCR5 mRNA |
CTD |
PMID:26345256 |
|
NCBI chr 8:133,192,398...133,215,599
Ensembl chr 8:133,197,032...133,215,614
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of CCT8 protein |
CTD |
PMID:29733421 |
|
NCBI chr11:27,130,172...27,141,881
Ensembl chr11:27,130,172...27,141,881
|
|
G |
Cd36 |
CD36 molecule |
decreases expression |
ISO |
Bleomycin results in decreased expression of CD36 mRNA |
CTD |
PMID:29408570 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cd86 |
CD86 molecule |
decreases expression |
ISO |
Bleomycin results in decreased expression of CD86 mRNA |
CTD |
PMID:29720568 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Cdc20 |
cell division cycle 20 |
increases expression |
ISO |
Bleomycin results in increased expression of CDC20 mRNA |
CTD |
PMID:26345256 |
|
NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions decreases expression |
ISO |
12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [Bleomycin results in decreased expression of CDH1 mRNA]; 12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [Bleomycin results in decreased expression of CDH1 protein]; Dexamethasone inhibits the reaction [Bleomycin results in decreased expression of CDH1 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in decreased expression of CDH1 protein]; Grape Seed Extract inhibits the reaction [Bleomycin results in decreased expression of CDH1 mRNA]; Grape Seed Extract inhibits the reaction [Bleomycin results in decreased expression of CDH1 protein] Bleomycin results in decreased expression of CDH1 mRNA; Bleomycin results in decreased expression of CDH1 protein |
CTD |
PMID:28300665 PMID:28694203 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Bleomycin results in increased expression of CDKN1A mRNA |
CTD |
PMID:26345256 PMID:29720568 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression increases response to substance multiple interactions decreases response to substance |
ISO |
Bleomycin results in increased expression of CEBPB mRNA CEBPB protein results in increased susceptibility to Bleomycin CEBPB protein affects the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; CEBPB protein affects the reaction [Bleomycin results in increased expression of CCL2 mRNA]; CEBPB protein affects the reaction [Bleomycin results in increased expression of IL1B mRNA]; CEBPB protein affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; CEBPB protein affects the reaction [Bleomycin results in increased expression of TNF mRNA] CEBPB gene mutant form results in decreased susceptibility to Bleomycin |
CTD |
PMID:17177178 PMID:21998664 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases expression |
EXP |
Bleomycin results in decreased expression of CES1 protein |
CTD |
PMID:25933445 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Cfl1 |
cofilin 1 |
increases expression |
EXP |
Bleomycin results in increased expression of CFL1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:220,869,805...220,873,337
Ensembl chr 1:220,869,805...220,873,337
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases phosphorylation multiple interactions |
ISO |
Bleomycin results in increased phosphorylation of CHEK2 protein resveratrol promotes the reaction [Bleomycin results in increased phosphorylation of CHEK2 protein] |
CTD |
PMID:24933654 |
|
NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
decreases expression |
EXP |
Bleomycin results in decreased expression of CHRNB2 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 2:189,088,570...189,096,785
Ensembl chr 2:189,088,570...189,096,785
|
|
G |
Ckb |
creatine kinase B |
increases expression |
EXP |
Bleomycin results in increased expression of CKB protein |
CTD |
PMID:25933445 |
|
NCBI chr 6:136,142,956...136,145,838
Ensembl chr 6:136,142,956...136,145,837
|
|
G |
Clcn5 |
chloride voltage-gated channel 5 |
increases expression |
EXP |
Bleomycin results in increased expression of CLCN5 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr X:16,170,585...16,196,691
Ensembl chr X:16,050,780...16,196,789
|
|
G |
Cldn4 |
claudin 4 |
increases expression |
ISO |
Bleomycin results in increased expression of CLDN4 mRNA |
CTD |
PMID:26345256 |
|
NCBI chr12:24,761,210...24,763,008
Ensembl chr12:24,761,210...24,763,005
|
|
G |
Clic4 |
chloride intracellular channel 4 |
decreases expression |
EXP |
Bleomycin results in decreased expression of CLIC4 protein |
CTD |
PMID:25933445 |
|
NCBI chr 5:153,568,937...153,625,669
Ensembl chr 5:153,568,745...153,625,869
|
|
G |
Clic5 |
chloride intracellular channel 5 |
decreases expression |
EXP |
Bleomycin results in decreased expression of CLIC5 protein |
CTD |
PMID:25933445 |
|
NCBI chr 9:19,121,676...19,372,673
Ensembl chr 9:19,121,677...19,372,673
|
|
G |
Cltc |
clathrin heavy chain |
decreases expression |
EXP |
Bleomycin results in decreased expression of CLTC protein |
CTD |
PMID:25933445 |
|
NCBI chr10:74,014,560...74,070,578
Ensembl chr10:74,014,562...74,070,266
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of CNR1 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions increases expression decreases expression |
ISO EXP |
[Bleomycin co-treated with Soot] results in increased expression of COL1A1 protein; Arsenic Trioxide inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; Arsenic Trioxide inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein]; CCR2 gene mutant form inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein]; Enalapril inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; Grape Seed Extract inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; Grape Seed Extract inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein]; Rosiglitazone inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; S1PR5 protein affects the reaction [Bleomycin results in increased expression of COL1A1 mRNA] MIR101-1 mRNA inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA] Bleomycin results in increased expression of COL1A1 mRNA; Bleomycin results in increased expression of COL1A1 protein Bleomycin results in decreased expression of COL1A1 protein Curcumin inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; Curcumin inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein]; Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; Phytochemicals inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA] |
CTD |
PMID:12003776 PMID:14609568 PMID:17434272 PMID:19147827 PMID:24762191 PMID:25933445 PMID:26093215 PMID:26345256 PMID:28300665 PMID:28726637 PMID:29033951 PMID:31302203 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
increases expression decreases expression multiple interactions |
ISO EXP |
Bleomycin results in increased expression of COL1A2 mRNA Bleomycin results in decreased expression of COL1A2 protein rosiglitazone inhibits the reaction [Bleomycin results in increased expression of COL1A2 mRNA] |
CTD |
PMID:19147827 PMID:25933445 |
|
NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression multiple interactions increases expression |
EXP ISO |
Bleomycin results in decreased expression of COL3A1 protein MIR101-1 mRNA inhibits the reaction [Bleomycin results in increased expression of COL3A1 mRNA] |
CTD |
PMID:25933445 PMID:26817844 PMID:28726637 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
decreases expression |
EXP |
Bleomycin results in decreased expression of COL5A1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 3:6,430,180...6,581,010
Ensembl chr 3:6,430,201...6,578,882
|
|
G |
Comp |
cartilage oligomeric matrix protein |
multiple interactions |
ISO |
[S1PR5 protein affects the susceptibility to Bleomycin] which affects the expression of COMP protein |
CTD |
PMID:29033951 |
|
NCBI chr16:20,798,437...20,807,070
Ensembl chr16:20,798,437...20,807,070
|
|
G |
Cp |
ceruloplasmin |
multiple interactions increases expression |
ISO |
tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of CP protein] |
CTD |
PMID:12624602 |
|
NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
|
|
G |
Crip2 |
cysteine-rich protein 2 |
affects expression |
EXP |
Bleomycin affects the expression of CRIP2 protein |
CTD |
PMID:25933445 |
|
NCBI chr 6:137,953,545...137,958,491
Ensembl chr 6:137,953,545...137,958,490
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression decreases expression |
ISO |
Bleomycin results in increased expression of CSF2 protein Bleomycin results in decreased expression of CSF2 mRNA |
CTD |
PMID:18684396 PMID:29720568 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Csf3 |
colony stimulating factor 3 |
decreases expression |
EXP |
Bleomycin results in decreased expression of CSF3 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157
|
|
G |
Csrp1 |
cysteine and glycine-rich protein 1 |
increases expression |
EXP |
Bleomycin results in increased expression of CSRP1 protein |
CTD |
PMID:25933445 |
|
NCBI chr13:52,553,843...52,575,054
Ensembl chr13:52,553,775...52,575,051
|
|
G |
Ctsa |
cathepsin A |
affects expression |
ISO |
Bleomycin affects the expression of CTSA mRNA |
CTD |
PMID:26345256 |
|
NCBI chr 3:161,298,750...161,304,627
Ensembl chr 3:161,298,962...161,304,625
|
|
G |
Ctsb |
cathepsin B |
affects expression |
ISO |
Bleomycin affects the expression of CTSB mRNA |
CTD |
PMID:26345256 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Ctsh |
cathepsin H |
affects expression |
ISO |
Bleomycin affects the expression of CTSH mRNA |
CTD |
PMID:26345256 |
|
NCBI chr 8:97,439,155...97,458,293
Ensembl chr 8:97,439,161...97,458,287
|
|
G |
Ctss |
cathepsin S |
increases expression |
ISO |
Bleomycin results in increased expression of CTSS mRNA |
CTD |
PMID:19101991 |
|
NCBI chr 2:197,655,780...197,679,768
Ensembl chr 2:197,655,786...197,679,458
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression decreases expression |
ISO |
Bleomycin results in increased expression of CXCL10 mRNA Bleomycin results in decreased expression of CXCL10 mRNA |
CTD |
PMID:26345256 PMID:29720568 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
ISO |
Bleomycin results in increased expression of CXCL12 mRNA |
CTD |
PMID:29720568 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cxcl13 |
C-X-C motif chemokine ligand 13 |
affects expression |
ISO |
Bleomycin affects the expression of CXCL13 mRNA |
CTD |
PMID:26345256 |
|
NCBI chr14:15,253,146...15,258,221
Ensembl chr14:15,253,125...15,258,207
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions increases secretion |
ISO |
Bleomycin results in increased expression of CXCL2 protein 3-aminobenzamide inhibits the reaction [Bleomycin results in increased secretion of CXCL2 protein]; Calcitriol inhibits the reaction [Bleomycin results in increased expression of CXCL2 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Bleomycin results in increased secretion of CXCL2 protein]; TRPM2 gene mutant form inhibits the reaction [Bleomycin results in increased secretion of CXCL2 protein] |
CTD |
PMID:18684396 PMID:22687607 PMID:26520185 PMID:26600069 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases secretion |
ISO |
TRPM2 gene mutant form inhibits the reaction [Bleomycin results in increased secretion of CXCL1 protein] |
CTD |
PMID:26600069 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
increases expression |
ISO |
Bleomycin results in increased expression of CXCL9 protein |
CTD |
PMID:29175452 |
|
NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
EXP |
Bleomycin affects the localization of CYCS protein |
CTD |
PMID:15371238 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Dbi |
diazepam binding inhibitor, acyl-CoA binding protein |
increases expression |
EXP |
Bleomycin results in increased expression of DBI protein |
CTD |
PMID:25933445 |
|
NCBI chr13:36,147,667...36,156,076
Ensembl chr13:36,117,119...36,174,908
|
|
G |
Des |
desmin |
increases expression |
EXP |
Bleomycin results in increased expression of DES protein |
CTD |
PMID:25933445 |
|
NCBI chr 9:82,556,574...82,564,288
Ensembl chr 9:82,556,573...82,564,294
|
|
G |
Dlat |
dihydrolipoamide S-acetyltransferase |
decreases expression |
ISO |
Bleomycin results in decreased expression of DLAT protein |
CTD |
PMID:29733421 |
|
NCBI chr 8:55,062,549...55,087,832
Ensembl chr 8:55,062,551...55,087,832
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
increases expression |
EXP ISO |
Bleomycin results in increased expression of DLD protein |
CTD |
PMID:25933445 PMID:29733421 |
|
NCBI chr 6:50,597,677...50,618,694
Ensembl chr 6:50,597,677...50,618,694
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
increases expression |
ISO |
Bleomycin results in increased expression of DLK1 protein |
CTD |
PMID:29175452 |
|
NCBI chr 6:133,576,513...133,583,751
Ensembl chr 6:133,552,821...133,583,751
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
affects response to substance |
ISO |
DNMT1 protein affects the susceptibility to Bleomycin |
CTD |
PMID:17991895 |
|
NCBI chr 8:21,922,515...21,968,495
Ensembl chr 8:21,922,515...21,968,495
|
|
G |
Dpep1 |
dipeptidase 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of DPEP1 protein |
CTD |
PMID:25933445 |
|
NCBI chr19:55,973,447...55,998,830
Ensembl chr19:55,982,740...55,998,208
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of ECH1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:87,009,798...87,015,996
Ensembl chr 1:87,009,730...87,016,005
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases expression |
EXP |
Phytochemicals inhibits the reaction [Bleomycin results in increased expression of EDN1 mRNA] |
CTD |
PMID:26093215 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
increases expression |
ISO |
Bleomycin results in increased expression of EEF1A1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 8:85,838,594...85,841,816
Ensembl chr 8:85,838,869...85,840,818
|
|
G |
Egr1 |
early growth response 1 |
increases expression affects expression multiple interactions |
ISO |
Bleomycin results in increased expression of EGR1 mRNA Bleomycin affects the expression of EGR1 mRNA rosiglitazone inhibits the reaction [Bleomycin results in increased expression of EGR1 mRNA] |
CTD |
PMID:19147827 PMID:26345256 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Egr2 |
early growth response 2 |
affects expression |
ISO |
Bleomycin affects the expression of EGR2 mRNA |
CTD |
PMID:26345256 |
|
NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
|
|
G |
Ehd1 |
EH-domain containing 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of EHD1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:221,644,867...221,667,242
Ensembl chr 1:221,644,867...221,667,239
|
|
G |
Ehd2 |
EH-domain containing 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of EHD2 protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:77,847,599...77,865,870
Ensembl chr 1:77,847,600...77,865,870
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
increases expression |
EXP |
Bleomycin results in increased expression of EIF5A protein |
CTD |
PMID:25933445 |
|
NCBI chr10:56,527,075...56,531,615
Ensembl chr10:56,527,085...56,531,483
|
|
G |
Eln |
elastin |
increases expression |
ISO |
Bleomycin results in increased expression of ELN mRNA |
CTD |
PMID:26817844 |
|
NCBI chr12:24,978,478...25,021,864
Ensembl chr12:24,978,483...25,021,863
|
|
G |
Epx |
eosinophil peroxidase |
increases expression |
EXP |
Bleomycin results in increased expression of EPX protein |
CTD |
PMID:26093215 |
|
NCBI chr10:75,160,690...75,171,774
Ensembl chr10:75,160,690...75,171,774
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
decreases expression |
ISO |
Bleomycin results in decreased expression of ETS1 mRNA |
CTD |
PMID:28726637 |
|
NCBI chr 8:33,756,634...33,879,625
Ensembl chr 8:33,816,386...33,879,625
|
|
G |
Ets2 |
ETS proto-oncogene 2, transcription factor |
decreases expression |
ISO |
Bleomycin results in decreased expression of ETS2 mRNA |
CTD |
PMID:28726637 |
|
NCBI chr11:36,075,709...36,092,495
Ensembl chr11:36,075,709...36,092,495
|
|
G |
Ezr |
ezrin |
decreases expression |
EXP |
Bleomycin results in decreased expression of EZR protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:47,287,872...47,331,412
Ensembl chr 1:47,287,874...47,331,412
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions increases expression |
EXP |
allyl sulfide inhibits the reaction [Bleomycin results in increased expression of F2RL1 mRNA]; allyl sulfide inhibits the reaction [Bleomycin results in increased expression of F2RL1 protein] Bleomycin results in increased expression of F2RL1 mRNA; Bleomycin results in increased expression of F2RL1 protein |
CTD |
PMID:23656969 |
|
NCBI chr 2:25,222,324...25,235,275
Ensembl chr 2:25,222,328...25,235,275
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
ISO |
Bleomycin results in decreased expression of FABP4 mRNA |
CTD |
PMID:29408570 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
Bleomycin results in increased expression of FASLG mRNA |
CTD |
PMID:11350791 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression multiple interactions |
EXP |
Bleomycin results in increased expression of FGF2 protein protocatechualdehyde inhibits the reaction [Bleomycin results in increased expression of FGF2 protein] |
CTD |
PMID:25582705 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
increases expression |
EXP |
Bleomycin results in increased expression of FHL1 protein |
CTD |
PMID:25933445 |
|
NCBI chr X:159,112,516...159,172,528
Ensembl chr X:159,112,880...159,172,524
|
|
G |
Fn1 |
fibronectin 1 |
increases expression multiple interactions |
EXP ISO |
Bleomycin results in increased expression of FN1 protein Bleomycin results in increased expression of FN1 mRNA; Bleomycin results in increased expression of FN1 protein [Bleomycin co-treated with Soot] results in increased expression of FN1 protein; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of FN1 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of FN1 protein]; Grape Seed Extract inhibits the reaction [Bleomycin results in increased expression of FN1 mRNA]; Grape Seed Extract inhibits the reaction [Bleomycin results in increased expression of FN1 protein]; Soot promotes the reaction [Bleomycin results in increased expression of FN1 mRNA] |
CTD |
PMID:25071917 PMID:25933445 PMID:26345256 PMID:26817844 PMID:28300665 PMID:31302203 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases activity |
ISO |
Bleomycin results in increased activity of FOS protein |
CTD |
PMID:12003776 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Foxp3 |
forkhead box P3 |
increases expression |
ISO |
Bleomycin results in increased expression of FOXP3 mRNA |
CTD |
PMID:29033951 |
|
NCBI chr X:15,753,175...15,768,648
Ensembl chr X:15,753,175...15,768,522
|
|
G |
Fshr |
follicle stimulating hormone receptor |
decreases expression |
EXP |
Bleomycin results in decreased expression of FSHR mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 6:12,796,383...12,997,817
Ensembl chr 6:12,796,383...12,997,817
|
|
G |
Fubp1 |
far upstream element binding protein 1 |
increases expression |
EXP |
Bleomycin results in increased expression of FUBP1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:257,425,676...257,452,745
Ensembl chr 2:257,425,679...257,449,568
|
|
G |
Fzd6 |
frizzled class receptor 6 |
increases expression multiple interactions |
ISO |
Bleomycin results in increased expression of FZD6 mRNA MIR101-1 mRNA inhibits the reaction [Bleomycin results in increased expression of FZD6 mRNA] |
CTD |
PMID:28726637 |
|
NCBI chr 7:77,898,329...77,931,034
Ensembl chr 7:77,899,322...77,931,029
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
decreases expression |
EXP |
Bleomycin results in decreased expression of GABRA4 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr14:39,154,072...39,230,994
Ensembl chr14:39,154,529...39,231,695
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of GABRB2 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr10:27,973,694...28,193,072
Ensembl chr10:27,973,681...28,187,565
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of GABRG2 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr10:27,090,913...27,179,786
Ensembl chr10:27,092,827...27,179,900
|
|
G |
Gabrr1 |
gamma-aminobutyric acid type A receptor subunit rho 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of GABRR1 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 5:48,374,048...48,411,170
Ensembl chr 5:48,374,096...48,411,170
|
|
G |
Ganab |
glucosidase II alpha subunit |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of GANAB protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:225,096,558...225,116,384
Ensembl chr 1:225,096,598...225,116,378
|
|
G |
Gas6 |
growth arrest specific 6 |
increases expression |
ISO |
Bleomycin results in increased expression of GAS6 protein |
CTD |
PMID:29175452 |
|
NCBI chr16:81,213,364...81,243,824
Ensembl chr16:81,213,364...81,243,757
|
|
G |
Gata3 |
GATA binding protein 3 |
increases expression multiple interactions |
ISO |
Bleomycin results in increased expression of GATA3 mRNA S1PR5 protein affects the reaction [Bleomycin results in increased expression of GATA3 mRNA] |
CTD |
PMID:29033951 |
|
NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681
|
|
G |
Gc |
GC, vitamin D binding protein |
increases expression |
EXP |
Bleomycin results in increased expression of GC protein |
CTD |
PMID:25933445 |
|
NCBI chr14:20,267,023...20,302,577
Ensembl chr14:20,266,891...20,302,581
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions decreases expression |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Bleomycin results in decreased expression of GCLC protein] |
CTD |
PMID:23570914 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gda |
guanine deaminase |
decreases expression |
EXP |
Bleomycin results in decreased expression of GDA protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:238,982,542...239,057,663
Ensembl chr 1:238,982,392...239,057,732
|
|
G |
Gpi |
glucose-6-phosphate isomerase |
decreases expression |
EXP |
Bleomycin results in decreased expression of GPI protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:90,063,411...90,091,287
Ensembl chr 1:90,063,411...90,091,287
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
affects expression |
EXP |
Bleomycin affects the expression of GPX1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of GRIA2 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 2:179,584,302...179,704,629
Ensembl chr 2:179,584,308...179,704,629
|
|
G |
Grik3 |
glutamate ionotropic receptor kainate type subunit 3 |
decreases expression |
EXP |
Bleomycin results in decreased expression of GRIK3 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 5:143,500,441...143,715,546
Ensembl chr 5:143,500,441...143,715,546
|
|
G |
Grpr |
gastrin releasing peptide receptor |
decreases expression |
EXP |
Bleomycin results in decreased expression of GRPR mRNA |
CTD |
PMID:15808516 |
|
NCBI chr X:32,746,259...32,786,266
Ensembl chr X:32,745,873...32,786,359
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation |
ISO |
[2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of GSK3B protein] which results in decreased susceptibility to Bleomycin; [Bleomycin results in increased phosphorylation of GSK3B protein] inhibits the reaction [GSK3B protein binds to and results in increased stability of NFKBIA protein] |
CTD |
PMID:19429264 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gsn |
gelsolin |
decreases expression |
EXP |
Bleomycin results in decreased expression of GSN protein |
CTD |
PMID:25933445 |
|
NCBI chr 3:14,456,106...14,508,922
Ensembl chr 3:14,467,330...14,508,911
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity multiple interactions |
EXP |
Bleomycin results in decreased activity of GSR protein tripterine inhibits the reaction [Bleomycin results in decreased activity of GSR protein] |
CTD |
PMID:26768587 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of GSTM1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
H1f0 |
H1.0 linker histone |
affects expression |
EXP |
Bleomycin affects the expression of H1F0 protein |
CTD |
PMID:25933445 |
|
NCBI chr 7:120,260,776...120,262,636
|
|
G |
H1f4 |
H1.4 linker histone, cluster member |
affects expression |
EXP |
Bleomycin affects the expression of H1F4 protein |
CTD |
PMID:25933445 |
|
NCBI chr17:43,734,461...43,735,120
Ensembl chr17:43,734,461...43,735,120
|
|
G |
H2ax |
H2A.X variant histone |
increases expression |
ISO |
Bleomycin results in increased expression of H2AX protein |
CTD |
PMID:25130544 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
decreases expression |
EXP |
Bleomycin results in decreased expression of HADHA protein |
CTD |
PMID:25933445 |
|
NCBI chr 6:27,589,840...27,628,921
Ensembl chr 6:27,589,657...27,629,175
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression |
ISO |
Bleomycin results in increased expression of HAVCR1 protein |
CTD |
PMID:29175452 |
|
NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
|
|
G |
Hbb |
hemoglobin subunit beta |
affects expression |
EXP |
Bleomycin affects the expression of HBB protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:168,971,269...168,972,680
Ensembl chr 1:168,971,274...168,972,725
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
Bleomycin results in increased expression of HBEGF mRNA |
CTD |
PMID:18684396 |
|
NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
|
|
G |
Hgf |
hepatocyte growth factor |
decreases expression multiple interactions increases expression increases secretion |
EXP ISO |
Bleomycin results in decreased expression of HGF mRNA; Bleomycin results in decreased expression of HGF protein Berberine inhibits the reaction [Bleomycin results in decreased expression of HGF mRNA] Bleomycin results in increased expression of HGF mRNA Bleomycin results in increased secretion of HGF protein Valsartan inhibits the reaction [Bleomycin results in decreased expression of HGF mRNA]; Valsartan inhibits the reaction [Bleomycin results in decreased expression of HGF protein] |
CTD |
PMID:16115399 PMID:22687607 PMID:29408570 |
|
NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
ISO |
[HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; Dinoprostone inhibits the reaction [Bleomycin results in increased expression of HIF1A mRNA]; HIF1A protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]] |
CTD |
PMID:28434932 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hist1h2bg |
histone cluster 1, H2bg |
decreases expression |
EXP |
Bleomycin results in decreased expression of HIST1H2BG protein |
CTD |
PMID:25933445 |
|
NCBI chr17:43,817,316...43,817,717
Ensembl chr17:43,817,378...43,817,720
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions increases expression |
EXP ISO |
protocatechualdehyde inhibits the reaction [Bleomycin results in increased expression of HMGB1 protein] Bleomycin inhibits the reaction [Azacitidine results in decreased expression of and results in increased secretion of HMGB1 protein]; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of HMGB1 mRNA] |
CTD |
PMID:25582705 PMID:32278510 |
|
NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions decreases expression |
ISO EXP |
Bleomycin results in increased expression of HMOX1 protein Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of HMOX1 mRNA]; Phytochemicals inhibits the reaction [Bleomycin results in increased expression of HMOX1 mRNA]; tripterine inhibits the reaction [Bleomycin results in decreased expression of HMOX1 protein] PPARA protein affects the reaction [Bleomycin results in increased expression of HMOX1 protein] |
CTD |
PMID:16317386 PMID:26093215 PMID:26768587 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
increases expression |
EXP |
Bleomycin results in increased expression of HNRNPA2B1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 4:81,237,496...81,241,281
Ensembl chr 4:81,237,496...81,241,282
|
|
G |
Hnrnpa3 |
heterogeneous nuclear ribonucleoprotein A3 |
increases expression |
EXP |
Bleomycin results in increased expression of HNRNPA3 protein |
CTD |
PMID:25933445 |
|
NCBI chr 3:62,481,222...62,491,356
Ensembl chr 3:62,481,323...62,487,227
|
|
G |
Hpx |
hemopexin |
increases expression |
EXP |
Bleomycin results in increased expression of HPX protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:170,423,558...170,431,066
Ensembl chr 1:170,423,483...170,431,073
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
EXP |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of HSP90AA1 protein |
CTD |
PMID:24478030 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
EXP |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of HSP90B1 protein |
CTD |
PMID:24478030 |
|
NCBI chr 7:27,226,570...27,240,533
Ensembl chr 7:27,226,569...27,240,533
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Bleomycin results in increased expression of HSPA5 protein |
CTD |
PMID:25933445 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of HSPB1 protein |
CTD |
PMID:25933445 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
EXP ISO |
Bleomycin results in increased expression of HSPE1 protein |
CTD |
PMID:25933445 PMID:29733421 |
|
NCBI chr 9:61,691,246...61,724,948
Ensembl chr 9:61,692,154...61,694,599
|
|
G |
Htr1f |
5-hydroxytryptamine receptor 1F |
decreases expression |
EXP |
Bleomycin results in decreased expression of HTR1F mRNA |
CTD |
PMID:15808516 |
|
NCBI chr11:1,982,113...1,983,513
Ensembl chr11:1,982,113...1,983,513
|
|
G |
Htr5a |
5-hydroxytryptamine receptor 5A |
decreases expression |
EXP |
Bleomycin results in decreased expression of HTR5A mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 4:199,916...209,599
Ensembl chr 4:199,916...209,599
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
Bleomycin results in increased expression of ICAM1 mRNA |
CTD |
PMID:29033951 PMID:29720568 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of IDH2 protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
G |
Ifng |
interferon gamma |
increases expression multiple interactions decreases expression |
ISO |
Bleomycin results in increased expression of IFNG mRNA [SPL-334 co-treated with Bleomycin] results in increased expression of IFNG protein Bleomycin results in decreased expression of IFNG mRNA |
CTD |
PMID:11350791 PMID:25071917 PMID:26209236 PMID:29408570 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
Bleomycin results in increased expression of IGF1 mRNA |
CTD |
PMID:1705203 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Il10 |
interleukin 10 |
increases expression |
ISO |
Bleomycin results in increased expression of IL10 protein |
CTD |
PMID:29175452 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
Bleomycin results in increased expression of IL12B mRNA; Bleomycin results in increased expression of IL12B protein |
CTD |
PMID:11350791 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il12rb2 |
interleukin 12 receptor subunit beta 2 |
increases expression |
ISO |
Bleomycin results in increased expression of IL12RB2 mRNA |
CTD |
PMID:11350791 |
|
NCBI chr 4:98,049,195...98,141,562
Ensembl chr 4:98,052,842...98,141,482
|
|
G |
Il13 |
interleukin 13 |
decreases response to substance multiple interactions |
ISO |
IL13 gene mutant form results in decreased susceptibility to Bleomycin IL13 protein affects the reaction [Bleomycin results in increased expression of RETNLA mRNA] |
CTD |
PMID:15322207 |
|
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases expression |
ISO |
IL1A protein promotes the reaction [Bleomycin results in increased expression of CAT protein]; IL1A protein promotes the reaction [Bleomycin results in increased expression of SOD1 protein]; IL1A protein promotes the reaction [Bleomycin results in increased expression of SOD2 protein] Bleomycin results in increased expression of IL1A protein |
CTD |
PMID:8317554 PMID:29175452 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion affects expression increases expression |
ISO EXP |
12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [Bleomycin results in increased expression of IL1B mRNA]; 12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [Bleomycin results in increased expression of IL1B protein]; 2-((dimethylamino)methyl)-9-hydroxythieno(2,3-c)isoquinolin-5(4H)-one inhibits the reaction [Bleomycin results in increased expression of IL1B protein]; Calcitriol inhibits the reaction [Bleomycin results in increased expression of IL1B mRNA]; CEBPB protein affects the reaction [Bleomycin results in increased expression of IL1B mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of IL1B mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of IL1B protein]; Grape Seed Extract inhibits the reaction [Bleomycin results in increased expression of IL1B mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Bleomycin results in increased expression of IL1B mRNA]; pirinixic acid inhibits the reaction [Bleomycin results in increased expression of IL1B protein]; PPARA protein affects the reaction [Bleomycin results in increased expression of IL1B protein]; Rosiglitazone inhibits the reaction [Bleomycin results in increased expression of IL1B protein]; TRPM2 gene mutant form inhibits the reaction [Bleomycin results in increased secretion of IL1B protein]; verlukast inhibits the reaction [Bleomycin results in increased expression of IL1B protein]; zileuton inhibits the reaction [Bleomycin results in increased expression of IL1B protein] Bleomycin affects the expression of IL1B mRNA IL1B protein promotes the reaction [Bleomycin results in increased expression of CAT protein]; IL1B protein promotes the reaction [Bleomycin results in increased expression of SOD1 protein]; IL1B protein promotes the reaction [Bleomycin results in increased expression of SOD2 protein] Bleomycin results in increased expression of IL1B mRNA; Bleomycin results in increased expression of IL1B protein Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of IL1B mRNA]; Phytochemicals inhibits the reaction [Bleomycin results in increased expression of IL1B mRNA]; Resveratrol inhibits the reaction [Bleomycin results in increased expression of IL1B protein] |
CTD |
PMID:8317554 PMID:8473757 PMID:16317386 PMID:17035056 PMID:17118201 PMID:17177178 PMID:19147827 PMID:22687607 PMID:26093215 PMID:26520185 PMID:26526764 PMID:26600069 PMID:27704718 PMID:28300665 PMID:28694203 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il4 |
interleukin 4 |
increases expression affects response to substance multiple interactions decreases response to substance |
ISO |
Bleomycin results in increased expression of IL4 mRNA IL4 protein affects the susceptibility to Bleomycin IL4 protein affects the reaction [Bleomycin results in increased expression of RETNLA mRNA] IL4 gene mutant form results in decreased susceptibility to Bleomycin |
CTD |
PMID:11554783 PMID:12574379 PMID:15322207 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO EXP |
Bleomycin results in increased expression of IL6 protein Calcitriol inhibits the reaction [Bleomycin results in increased expression of IL6 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of IL6 mRNA]; Grape Seed Extract inhibits the reaction [Bleomycin results in increased expression of IL6 mRNA]; Oils, Volatile inhibits the reaction [Bleomycin results in increased expression of IL6 protein]; SPL-334 inhibits the reaction [Bleomycin results in increased expression of IL6 protein] Bleomycin results in increased expression of IL6 mRNA; Bleomycin results in increased expression of IL6 protein allyl sulfide inhibits the reaction [Bleomycin results in increased expression of IL6 protein]; Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of IL6 mRNA]; Phytochemicals inhibits the reaction [Bleomycin results in increased expression of IL6 mRNA]; resveratrol inhibits the reaction [Bleomycin results in increased expression of IL6 protein] |
CTD |
PMID:17035056 PMID:18684396 PMID:23656969 PMID:25071917 PMID:26093215 PMID:26209236 PMID:26520185 PMID:28300665 PMID:28850077 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Jpt1 |
Jupiter microtubule associated homolog 1 |
increases expression |
EXP |
Bleomycin results in increased expression of JPT1 protein |
CTD |
PMID:25933445 |
|
NCBI chr10:104,057,739...104,075,776
Ensembl chr10:104,057,697...104,075,777
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases activity |
ISO |
Bleomycin results in increased activity of JUN protein |
CTD |
PMID:12003776 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
decreases expression multiple interactions |
EXP |
Bleomycin results in decreased expression of KEAP1 protein tripterine inhibits the reaction [Bleomycin results in decreased expression of KEAP1 protein] |
CTD |
PMID:26768587 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Khsrp |
KH-type splicing regulatory protein |
increases expression |
EXP |
Bleomycin results in increased expression of KHSRP protein |
CTD |
PMID:25933445 |
|
NCBI chr 9:10,013,795...10,023,670
Ensembl chr 9:10,013,854...10,022,924
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
increases expression multiple interactions |
ISO |
Bleomycin results in increased expression of KIT protein [Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in increased expression of KIT protein |
CTD |
PMID:29733421 |
|
NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
|
|
G |
Kl |
Klotho |
decreases expression |
ISO |
Bleomycin results in decreased expression of KL mRNA |
CTD |
PMID:29408570 |
|
NCBI chr12:942,974...987,206
Ensembl chr12:943,006...987,551
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions |
ISO |
[Bleomycin co-treated with 1-nitropyrene] results in increased mutagenesis of KRAS gene |
CTD |
PMID:12616606 |
|
NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
|
|
G |
Krt19 |
keratin 19 |
decreases expression |
EXP |
Bleomycin results in decreased expression of KRT19 protein |
CTD |
PMID:25933445 |
|
NCBI chr10:88,055,843...88,060,560
Ensembl chr10:88,055,841...88,060,561
|
|
G |
Lap3 |
leucine aminopeptidase 3 |
increases expression |
EXP |
Bleomycin results in increased expression of LAP3 protein |
CTD |
PMID:25933445 |
|
NCBI chr14:70,102,813...70,121,797
Ensembl chr14:70,102,814...70,121,797
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
increases expression |
EXP |
Bleomycin results in increased expression of LASP1 protein |
CTD |
PMID:25933445 |
|
NCBI chr10:85,744,662...85,785,130
Ensembl chr10:85,744,568...85,785,133
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
Bleomycin results in increased expression of LCN2 mRNA; Bleomycin results in increased expression of LCN2 protein |
CTD |
PMID:26345256 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Lep |
leptin |
increases expression |
ISO |
Bleomycin results in increased expression of LEP protein |
CTD |
PMID:29175452 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lgals3 |
galectin 3 |
increases expression multiple interactions |
ISO |
Bleomycin results in increased expression of LGALS3 protein NOS2 protein affects the reaction [Bleomycin results in increased expression of LGALS3 protein] |
CTD |
PMID:26526764 |
|
NCBI chr15:24,153,602...24,165,537
Ensembl chr15:24,141,651...24,165,537
|
|
G |
Lhx1 |
LIM homeobox 1 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of LHX1 mRNA |
CTD |
PMID:29733421 |
|
NCBI chr10:71,843,991...71,849,293
Ensembl chr10:71,843,991...71,849,293
|
|
G |
Lmna |
lamin A/C |
increases expression |
EXP |
Bleomycin results in increased expression of LMNA protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:187,842,884...187,863,552
Ensembl chr 2:187,842,885...187,863,516
|
|
G |
Lyz2 |
lysozyme 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of LYZ protein |
CTD |
PMID:25933445 |
|
NCBI chr 7:60,335,968...60,341,264
Ensembl chr 7:60,335,969...60,341,264
|
|
G |
Macroh2a1 |
macroH2A.1 histone |
decreases expression |
EXP |
Bleomycin results in decreased expression of MACROH2A1 protein |
CTD |
PMID:25933445 |
|
NCBI chr17:9,282,109...9,344,698
Ensembl chr17:9,282,675...9,344,678
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression multiple interactions |
ISO |
Bleomycin results in increased expression of MAP1LC3B protein modified form Soot inhibits the reaction [Bleomycin results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:31302203 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Bleomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein; U 0126 inhibits the reaction [Bleomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:23570914 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Bleomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein; U 0126 inhibits the reaction [Bleomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:23570914 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Marcks |
myristoylated alanine rich protein kinase C substrate |
decreases expression |
EXP |
Bleomycin results in decreased expression of MARCKS protein |
CTD |
PMID:25933445 |
|
NCBI chr20:42,966,140...42,971,838
Ensembl chr20:42,966,140...42,971,838
|
|
G |
Mdh2 |
malate dehydrogenase 2 |
decreases expression multiple interactions |
EXP ISO |
Bleomycin results in decreased expression of MDH2 protein [Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of MDH2 protein |
CTD |
PMID:25933445 PMID:29733421 |
|
NCBI chr12:23,941,451...23,954,406
Ensembl chr12:23,941,448...23,954,431
|
|
G |
Mecp2 |
methyl CpG binding protein 2 |
affects response to substance |
ISO |
MECP2 protein affects the susceptibility to Bleomycin |
CTD |
PMID:21435439 |
|
NCBI chr X:156,650,389...156,713,813
Ensembl chr X:156,655,960...156,705,233
|
|
G |
Mertk |
MER proto-oncogene, tyrosine kinase |
multiple interactions increases phosphorylation |
ISO |
Bleomycin affects the localization of and affects the expression of MERTK protein Bleomycin results in increased phosphorylation of MERTK protein |
CTD |
PMID:22687607 |
|
NCBI chr 3:121,235,230...121,340,932
Ensembl chr 3:121,235,119...121,342,444
|
|
G |
Mif |
macrophage migration inhibitory factor |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIF protein |
CTD |
PMID:25933445 |
|
NCBI chr20:13,715,219...13,732,980
Ensembl chr20:13,732,198...13,732,859
|
|
G |
Mir100 |
microRNA 100 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR100 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 8:45,746,948...45,747,027
Ensembl chr 8:45,746,948...45,747,027
|
|
G |
Mir101-2 |
microRNA 101-2 |
decreases expression |
EXP ISO |
Bleomycin results in decreased expression of MIR101B mRNA |
CTD |
PMID:25933445 PMID:28726637 |
|
NCBI chr 1:247,263,723...247,263,819
Ensembl chr 1:247,263,723...247,263,819
|
|
G |
Mir101a |
microRNA 101a |
multiple interactions decreases expression |
ISO EXP |
MIR101-1 mRNA inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; MIR101-1 mRNA inhibits the reaction [Bleomycin results in increased expression of COL3A1 mRNA]; MIR101-1 mRNA inhibits the reaction [Bleomycin results in increased expression of FZD6 mRNA]; MIR101-1 mRNA inhibits the reaction [Bleomycin results in increased expression of NFATC2 mRNA]; MIR101-1 mRNA inhibits the reaction [Bleomycin results in increased expression of TGFBR1 mRNA] Bleomycin results in decreased expression of MIR101A mRNA |
CTD |
PMID:25933445 PMID:28726637 |
|
NCBI chr 5:120,168,437...120,168,511
Ensembl chr 5:120,168,433...120,168,515
|
|
G |
Mir106b |
microRNA 106b |
affects expression |
EXP |
Bleomycin affects the expression of MIR106B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr12:19,307,752...19,307,833
Ensembl chr12:19,307,752...19,307,833
|
|
G |
Mir107 |
microRNA 107 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR107 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 1:253,128,250...253,128,336
Ensembl chr 1:253,128,250...253,128,336
|
|
G |
Mir10a |
microRNA 10a |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR10A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:84,165,950...84,166,059
Ensembl chr10:84,165,950...84,166,059
|
|
G |
Mir10b |
microRNA 10b |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR10B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 3:61,647,978...61,648,086
Ensembl chr 3:61,647,978...61,648,086
|
|
G |
Mir1224 |
microRNA 1224 |
increases expression |
EXP |
Bleomycin results in increased expression of MIR1224 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr11:83,992,628...83,992,712
Ensembl chr11:83,992,628...83,992,712
|
|
G |
Mir1249 |
microRNA 1249 |
affects expression |
EXP |
Bleomycin affects the expression of MIR1249 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 7:125,861,192...125,861,311
Ensembl chr 7:125,861,192...125,861,311
|
|
G |
Mir125a |
microRNA 125a |
affects expression |
EXP |
Bleomycin affects the expression of MIR125A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 1:59,704,827...59,704,911
Ensembl chr 1:59,704,827...59,704,911
|
|
G |
Mir126b |
microRNA 126b |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR126 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 3:4,042,488...4,042,560
|
|
G |
Mir130a |
microRNA 130a |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR130A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 3:72,141,037...72,141,124
Ensembl chr 3:72,141,037...72,141,124
|
|
G |
Mir133a1 |
microRNA 133a-1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR133A1 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr18:2,052,478...2,052,564
|
|
G |
Mir133b |
microRNA 133b |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR133B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 9:26,795,649...26,795,732
Ensembl chr 9:26,795,649...26,795,732
|
|
G |
Mir140 |
microRNA 140 |
affects expression |
EXP |
Bleomycin affects the expression of MIR140 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr19:39,608,951...39,609,049
Ensembl chr19:39,608,951...39,609,049
|
|
G |
Mir141 |
microRNA 141 |
affects expression |
EXP |
Bleomycin affects the expression of MIR141 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 4:157,236,346...157,236,439
Ensembl chr 4:157,236,346...157,236,439
|
|
G |
Mir142 |
microRNA 142 |
decreases expression increases expression |
EXP |
Bleomycin results in decreased expression of MIR142 mRNA Bleomycin results in increased expression of MIR142 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:75,050,839...75,050,925
Ensembl chr10:75,050,832...75,050,942
|
|
G |
Mir143 |
microRNA 143 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR143 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr18:56,971,273...56,971,377
Ensembl chr18:56,971,273...56,971,377
|
|
G |
Mir144 |
microRNA 144 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR144 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:65,291,365...65,291,447
Ensembl chr10:65,291,365...65,291,447
|
|
G |
Mir145 |
microRNA 145 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR145 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr18:56,969,907...56,969,994
Ensembl chr18:56,969,907...56,969,994
|
|
G |
Mir146a |
microRNA 146a |
affects expression |
EXP |
Bleomycin affects the expression of MIR146A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:28,962,476...28,962,570
Ensembl chr10:28,962,476...28,962,570
|
|
G |
Mir146b |
microRNA 146b |
increases expression |
EXP |
Bleomycin results in increased expression of MIR146B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 1:266,089,488...266,089,575
Ensembl chr 1:266,089,488...266,089,575
|
|
G |
Mir148b |
microRNA 148b |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR148B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 7:144,912,038...144,912,134
Ensembl chr 7:144,912,038...144,912,134
|
|
G |
Mir150 |
microRNA 150 |
affects expression |
EXP |
Bleomycin affects the expression of MIR150 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 1:101,115,974...101,116,058
Ensembl chr 1:101,115,974...101,116,058
|
|
G |
Mir151 |
microRNA 151 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR151 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 7:114,485,547...114,485,643
|
|
G |
Mir152 |
microRNA 152 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR152 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:84,719,319...84,719,403
Ensembl chr10:84,719,319...84,719,403
|
|
G |
Mir15b |
microRNA 15b |
affects expression |
EXP |
Bleomycin affects the expression of MIR15B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 2:165,605,923...165,606,020
Ensembl chr 2:165,605,923...165,606,020
|
|
G |
Mir16 |
microRNA 16 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR16 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 2:165,606,072...165,606,166
Ensembl chr 2:165,606,072...165,606,166
|
|
G |
Mir17 |
microRNA 17 |
affects expression |
EXP |
Bleomycin affects the expression of MIR17 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr15:100,179,879...100,179,962
Ensembl chr15:100,179,879...100,179,962
|
|
G |
Mir181c |
microRNA 181c |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR181C mRNA |
CTD |
PMID:25933445 |
|
NCBI chr19:25,290,211...25,290,316
Ensembl chr19:25,290,211...25,290,316
|
|
G |
Mir181d |
microRNA 181d |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR181D mRNA |
CTD |
PMID:25933445 |
|
NCBI chr19:25,290,051...25,290,133
Ensembl chr19:25,290,051...25,290,133
|
|
G |
Mir183 |
microRNA 183 |
affects expression |
EXP |
Bleomycin affects the expression of MIR183 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 4:57,463,569...57,463,678
Ensembl chr 4:57,463,569...57,463,678
|
|
G |
Mir185 |
microRNA 185 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR185 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr11:86,812,702...86,812,781
Ensembl chr11:86,812,702...86,812,781
|
|
G |
Mir186 |
microRNA 186 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR186 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 2:263,873,759...263,873,844
Ensembl chr 2:263,873,759...263,873,844
|
|
G |
Mir188 |
microRNA 188 |
affects expression |
EXP |
Bleomycin affects the expression of MIR188 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:16,110,270...16,110,349
Ensembl chr X:16,110,270...16,110,349
|
|
G |
Mir18a |
microRNA 18a |
increases expression |
EXP |
Bleomycin results in increased expression of MIR18A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr15:100,180,015...100,180,110
Ensembl chr15:100,180,015...100,180,110
|
|
G |
Mir193 |
microRNA 193 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR193 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:67,065,896...67,065,981
|
|
G |
Mir195 |
microRNA 195 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR195 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:56,845,301...56,845,387
Ensembl chr10:56,845,301...56,845,387
|
|
G |
Mir199a2 |
microRNA 199a-2 |
affects expression |
EXP |
Bleomycin affects the expression of MIR199A2 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr13:80,125,487...80,125,596
Ensembl chr13:80,125,487...80,125,596
|
|
G |
Mir19a |
microRNA 19a |
affects expression |
EXP |
Bleomycin affects the expression of MIR19A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr15:100,180,162...100,180,243
Ensembl chr15:100,180,162...100,180,243
|
|
G |
Mir200a |
microRNA 200a |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR200A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 5:173,489,366...173,489,454
|
|
G |
Mir200b |
microRNA 200b |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR200B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 5:173,490,144...173,490,238
Ensembl chr 5:173,490,144...173,490,238
|
|
G |
Mir200c |
microRNA 200c |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR200C mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 4:157,236,786...157,236,854
|
|
G |
Mir204 |
microRNA 204 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR204 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 1:240,403,000...240,403,109
Ensembl chr 1:240,403,000...240,403,109
|
|
G |
Mir20a |
microRNA 20a |
affects expression |
EXP |
Bleomycin affects the expression of MIR20A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr15:100,180,334...100,180,418
Ensembl chr15:100,180,334...100,180,418
|
|
G |
Mir20b |
microRNA 20b |
affects expression |
EXP |
Bleomycin affects the expression of MIR20B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:140,117,518...140,117,589
Ensembl chr X:140,117,518...140,117,589
|
|
G |
Mir21 |
microRNA 21 |
increases expression |
EXP |
Bleomycin results in increased expression of MIR21 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:73,902,210...73,902,301
Ensembl chr10:73,902,210...73,902,301
|
|
G |
Mir210 |
microRNA 210 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR210 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 1:214,208,355...214,208,464
|
|
G |
Mir211 |
microRNA 211 |
affects expression |
EXP |
Bleomycin affects the expression of MIR211 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 1:125,042,119...125,042,224
Ensembl chr 1:125,042,119...125,042,224
|
|
G |
Mir212 |
microRNA 212 |
affects expression |
EXP |
Bleomycin affects the expression of MIR212 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:62,014,702...62,014,812
Ensembl chr10:62,014,702...62,014,812
|
|
G |
Mir22 |
microRNA 22 |
affects expression |
EXP |
Bleomycin affects the expression of MIR22 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:62,299,592...62,299,686
Ensembl chr10:62,299,592...62,299,686
|
|
G |
Mir221 |
microRNA 221 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR221 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:3,684,480...3,684,588
Ensembl chr X:3,684,480...3,684,588
|
|
G |
Mir222 |
microRNA 222 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR222 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:3,683,919...3,684,021
Ensembl chr X:3,683,919...3,684,021
|
|
G |
Mir223 |
microRNA 223 |
affects expression |
EXP |
Bleomycin affects the expression of MIR223 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:65,367,812...65,367,921
Ensembl chr X:65,367,812...65,367,921
|
|
G |
Mir23a |
microRNA 23a |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR23A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr19:25,318,582...25,318,656
Ensembl chr19:25,318,582...25,318,656
|
|
G |
Mir23b |
microRNA 23b |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR23B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr17:823,222...823,318
Ensembl chr17:823,222...823,318
|
|
G |
Mir24-2 |
microRNA 24-2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR24-2 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr19:25,318,863...25,318,970
Ensembl chr19:25,318,863...25,318,970
|
|
G |
Mir25 |
microRNA 25 |
affects expression |
EXP |
Bleomycin affects the expression of MIR25 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr12:19,307,340...19,307,423
Ensembl chr12:19,307,340...19,307,423
|
|
G |
Mir26a |
microRNA 26a |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR26A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 8:127,714,441...127,714,530
Ensembl chr 8:127,714,441...127,714,530
|
|
G |
Mir26b |
microRNA 26b |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR26B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 9:81,675,275...81,675,359
Ensembl chr 9:81,675,275...81,675,359
|
|
G |
Mir27a |
microRNA 27a |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR27A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr19:25,318,736...25,318,822
Ensembl chr19:25,318,736...25,318,822
|
|
G |
Mir27b |
microRNA 27b |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR27B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr17:823,461...823,557
Ensembl chr17:823,461...823,557
|
|
G |
Mir28 |
microRNA 28 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR28 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr11:79,380,523...79,380,608
Ensembl chr11:79,380,523...79,380,608
|
|
G |
Mir290 |
microRNA 290 |
increases expression |
EXP |
Bleomycin results in increased expression of MIR290 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 1:64,538,705...64,538,785
Ensembl chr 1:64,538,705...64,538,785
|
|
G |
Mir296 |
microRNA 296 |
affects expression |
EXP |
Bleomycin affects the expression of MIR296 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 3:172,357,490...172,357,567
Ensembl chr 3:172,357,490...172,357,567
|
|
G |
Mir2985 |
microRNA 2985 |
affects expression |
EXP |
Bleomycin affects the expression of MIR2985 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 2:179,591,312...179,591,421
Ensembl chr 2:179,591,312...179,591,421
|
|
G |
Mir29a |
microRNA 29a |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR29A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 4:58,343,931...58,344,018
|
|
G |
Mir301a |
microRNA 301a |
affects expression |
EXP |
Bleomycin affects the expression of MIR301A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:74,417,746...74,417,845
Ensembl chr10:74,417,746...74,417,845
|
|
G |
Mir30a |
microRNA 30a |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR30A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 9:29,542,635...29,542,705
Ensembl chr 9:29,542,635...29,542,705
|
|
G |
Mir30b |
microRNA 30b |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR30B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 7:109,282,662...109,282,747
Ensembl chr 7:109,282,658...109,282,752
|
|
G |
Mir30c2 |
microRNA 30c-2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR30C2 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 9:29,562,376...29,562,459
Ensembl chr 9:29,562,376...29,562,459
|
|
G |
Mir30d |
microRNA 30d |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR30D mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 7:109,286,463...109,286,544
Ensembl chr 7:109,286,463...109,286,544
|
|
G |
Mir30e |
microRNA 30e |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR30E mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 5:139,702,872...139,702,963
Ensembl chr 5:139,702,872...139,702,963
|
|
G |
Mir31 |
microRNA 31 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR31 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 5:107,206,515...107,206,620
|
|
G |
Mir32 |
microRNA 32 |
increases expression |
EXP |
Bleomycin results in increased expression of MIR32 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 5:73,934,255...73,934,324
Ensembl chr 5:73,934,255...73,934,324
|
|
G |
Mir320a |
microRNA 320a |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR320A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr15:52,134,276...52,134,357
Ensembl chr15:52,134,276...52,134,357
|
|
G |
Mir322 |
microRNA 322 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR322 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:158,148,161...158,148,255
Ensembl chr X:158,148,161...158,148,255
|
|
G |
Mir324 |
microRNA 324 |
affects expression |
EXP |
Bleomycin affects the expression of MIR324 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:56,621,126...56,621,208
Ensembl chr10:56,621,124...56,621,212
|
|
G |
Mir326 |
microRNA 326 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR326 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 1:164,518,401...164,518,495
Ensembl chr 1:164,518,401...164,518,495
|
|
G |
Mir328 |
microRNA 328 |
affects expression |
EXP |
Bleomycin affects the expression of MIR328 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr19:37,263,199...37,263,282
Ensembl chr19:37,263,199...37,263,282
|
|
G |
Mir33 |
microRNA 33 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR33 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 7:123,431,612...123,431,680
Ensembl chr 7:123,431,612...123,431,680
|
|
G |
Mir330 |
microRNA 330 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR330 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 1:80,092,681...80,092,777
Ensembl chr 1:80,092,681...80,092,777
|
|
G |
Mir331 |
microRNA 331 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR331 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 7:34,881,095...34,881,190
Ensembl chr 7:34,881,095...34,881,190
|
|
G |
Mir340-1 |
microRNA mir-340-1 |
increases expression |
EXP |
Bleomycin results in increased expression of MIR340-1 mRNA |
CTD |
PMID:25933445 |
|
Ensembl chr10:35,558,983...35,559,080 Ensembl chr10:35,558,983...35,559,080
|
|
G |
Mir342 |
microRNA 342 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR342 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 6:132,561,169...132,561,267
Ensembl chr 6:132,561,169...132,561,267
|
|
G |
Mir345 |
microRNA 345 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR345 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 6:132,748,968...132,749,063
Ensembl chr 6:132,748,968...132,749,063
|
|
G |
Mir347 |
microRNA mir-347 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR347 mRNA |
CTD |
PMID:25933445 |
|
|
|
G |
Mir3473 |
microRNA 3473 |
increases expression |
EXP |
Bleomycin results in increased expression of MIR3473 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr13:44,719,335...44,719,401
Ensembl chr13:44,719,335...44,719,401
|
|
G |
Mir34a |
microRNA 34a |
affects expression |
EXP |
Bleomycin affects the expression of MIR34A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 5:167,092,491...167,092,592
Ensembl chr 5:167,092,491...167,092,592
|
|
G |
Mir34b |
microRNA 34b |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR34B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 8:55,492,542...55,492,625
Ensembl chr 8:55,492,542...55,492,625
|
|
G |
Mir34c |
microRNA 34c |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR34C mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 8:55,492,024...55,492,100
Ensembl chr 8:55,492,024...55,492,100
|
|
G |
Mir352 |
microRNA mir-352 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR352 mRNA |
CTD |
PMID:25933445 |
|
|
|
G |
Mir3545 |
microRNA 3545 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR203 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 6:136,704,947...136,705,061
Ensembl chr 6:136,704,947...136,705,061
|
|
G |
Mir3573 |
microRNA 3573 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR3573 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:68,892,972...68,893,043
Ensembl chr X:68,892,972...68,893,043
|
|
G |
Mir3584 |
microRNA 3584 |
affects expression |
EXP |
Bleomycin affects the expression of MIR3584 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 1:271,275,895...271,275,975
Ensembl chr 1:271,275,895...271,275,975
|
|
G |
Mir361 |
microRNA 361 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR361 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:84,708,911...84,708,980
Ensembl chr X:84,708,911...84,708,980
|
|
G |
Mir365b |
microRNA 365b |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR365B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:67,079,796...67,079,881
Ensembl chr10:67,079,796...67,079,881
|
|
G |
Mir374b |
microRNA 374b |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR374B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:74,443,648...74,443,715
Ensembl chr X:74,443,648...74,443,715
|
|
G |
Mir375 |
microRNA 375 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR375 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 9:82,161,716...82,161,790
Ensembl chr 9:82,161,716...82,161,790
|
|
G |
Mir378 |
microRNA 378 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR378 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr18:56,726,150...56,726,214
|
|
G |
Mir409 |
microRNA 409 |
affects expression |
EXP |
Bleomycin affects the expression of MIR409 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 6:133,893,419...133,893,495
|
|
G |
Mir423 |
microRNA 423 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR423 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:63,098,366...63,098,444
Ensembl chr10:63,098,360...63,098,453
|
|
G |
Mir425 |
microRNA 425 |
affects expression |
EXP |
Bleomycin affects the expression of MIR425 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 8:117,354,821...117,354,903
Ensembl chr 8:117,354,821...117,354,903
|
|
G |
Mir429 |
microRNA 429 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR429 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 5:173,488,331...173,488,415
Ensembl chr 5:173,488,331...173,488,415
|
|
G |
Mir449a |
microRNA 449a |
affects expression |
EXP |
Bleomycin affects the expression of MIR449A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 2:44,897,601...44,897,691
Ensembl chr 2:44,897,601...44,897,691
|
|
G |
Mir450a1 |
microRNA 450a-1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR450A1 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:158,153,377...158,153,467
Ensembl chr X:158,153,377...158,153,467
|
|
G |
Mir451a |
microRNA 451a |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR451A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:65,291,204...65,291,275
Ensembl chr10:65,291,204...65,291,275
|
|
G |
Mir494 |
microRNA 494 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR494 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 6:133,864,370...133,864,452
Ensembl chr 6:133,864,369...133,864,453
|
|
G |
Mir497 |
microRNA 497 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR497 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr10:56,844,977...56,845,045
Ensembl chr10:56,844,977...56,845,045
|
|
G |
Mir500 |
microRNA 500 |
affects expression |
EXP |
Bleomycin affects the expression of MIR500 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:16,121,332...16,121,411
Ensembl chr X:16,121,322...16,121,413
|
|
G |
Mir503 |
microRNA 503 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR503 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:158,148,476...158,148,546
Ensembl chr X:158,148,476...158,148,546
|
|
G |
Mir532 |
microRNA 532 |
affects expression |
EXP |
Bleomycin affects the expression of MIR532 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:16,109,870...16,109,948
Ensembl chr X:16,109,870...16,109,948
|
|
G |
Mir542 |
microRNA 542 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR542 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:158,152,146...158,152,224
Ensembl chr X:158,152,146...158,152,224
|
|
G |
Mir6215 |
microRNA 6215 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR6215 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 5:158,060,994...158,061,060
Ensembl chr 5:158,060,994...158,061,060
|
|
G |
Mir6216 |
microRNA 6216 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR6216 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 3:46,361,908...46,361,985
Ensembl chr 3:46,361,908...46,361,985
|
|
G |
Mir6328 |
microRNA 6328 |
affects expression |
EXP |
Bleomycin affects the expression of MIR6328 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr20:3,394,813...3,394,909
Ensembl chr20:3,394,813...3,394,909
|
|
G |
Mir652 |
microRNA 652 |
affects expression |
EXP |
Bleomycin affects the expression of MIR652 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:114,002,534...114,002,614
Ensembl chr X:114,002,534...114,002,614
|
|
G |
Mir93 |
microRNA 93 |
affects expression |
EXP |
Bleomycin affects the expression of MIR93 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr12:19,307,543...19,307,629
Ensembl chr12:19,307,543...19,307,629
|
|
G |
Mir96 |
microRNA 96 |
affects expression |
EXP |
Bleomycin affects the expression of MIR96 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 4:57,463,366...57,463,471
Ensembl chr 4:57,463,366...57,463,471
|
|
G |
Mir98 |
microRNA 98 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR98 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr X:21,583,875...21,583,982
Ensembl chr X:21,583,875...21,583,982
|
|
G |
Mir99a |
microRNA 99a |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR99A mRNA |
CTD |
PMID:25933445 |
|
NCBI chr11:16,052,153...16,052,233
Ensembl chr11:16,052,153...16,052,233
|
|
G |
Mir99b |
microRNA 99b |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIR99B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 1:59,704,216...59,704,285
Ensembl chr 1:59,704,216...59,704,285
|
|
G |
Mirlet7b |
microRNA let-7b |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIRLET7B mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 7:126,590,627...126,590,711
Ensembl chr 7:126,590,627...126,590,711
|
|
G |
Mirlet7d |
microRNA let-7d |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIRLET7D mRNA |
CTD |
PMID:25933445 |
|
NCBI chr17:16,419,980...16,420,077
Ensembl chr17:16,419,980...16,420,077
|
|
G |
Mirlet7i |
microRNA let-7i |
decreases expression |
EXP |
Bleomycin results in decreased expression of MIRLET7I mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 7:66,802,731...66,802,815
Ensembl chr 7:66,802,732...66,802,821
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
Bleomycin results in increased expression of MMP1 mRNA; Bleomycin results in increased expression of MMP1 protein |
CTD |
PMID:18684396 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression |
EXP ISO |
allyl sulfide inhibits the reaction [Bleomycin results in increased expression of MMP2 protein]; tripterine inhibits the reaction [Bleomycin results in increased expression of MMP2 protein] Bleomycin results in increased expression of MMP2 mRNA; Bleomycin results in increased expression of MMP2 protein |
CTD |
PMID:23656969 PMID:26345256 PMID:26768587 PMID:29175452 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions increases expression |
ISO |
[MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; Dinoprostone inhibits the reaction [Bleomycin results in increased expression of MMP3 mRNA]; MMP3 protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]] |
CTD |
PMID:28434932 |
|
NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
EXP ISO |
Bleomycin results in increased expression of MMP9 protein 12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [Bleomycin results in increased expression of MMP9 mRNA]; 12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [Bleomycin results in increased expression of MMP9 protein]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of MMP9 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of MMP9 protein]; Grape Seed Extract inhibits the reaction [Bleomycin results in increased expression of MMP9 protein]; NOS2 protein affects the reaction [Bleomycin results in increased expression of MMP9 protein] Bleomycin results in increased expression of MMP9 mRNA; Bleomycin results in increased expression of MMP9 protein allyl sulfide inhibits the reaction [Bleomycin results in increased expression of MMP9 protein]; tripterine inhibits the reaction [Bleomycin results in increased expression of MMP9 protein] |
CTD |
PMID:23656969 PMID:26526764 PMID:26768587 PMID:28300665 PMID:28694203 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases expression increases activity |
ISO EXP |
Oils, Volatile inhibits the reaction [Bleomycin results in increased activity of MPO protein]; pirinixic acid inhibits the reaction [Bleomycin results in increased activity of MPO protein]; verlukast inhibits the reaction [Bleomycin results in increased activity of MPO protein]; zileuton inhibits the reaction [Bleomycin results in increased activity of MPO protein] Bleomycin results in increased expression of MPO protein Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of MPO protein]; Phytochemicals inhibits the reaction [Bleomycin results in increased expression of MPO protein]; resveratrol inhibits the reaction [Bleomycin results in increased activity of MPO protein] |
CTD |
PMID:16317386 PMID:17035056 PMID:17118201 PMID:26093215 PMID:28850077 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
increases expression |
ISO |
Bleomycin results in increased expression of MRC1 mRNA |
CTD |
PMID:29033951 |
|
NCBI chr17:81,352,700...81,433,743
Ensembl chr17:81,352,700...81,433,743
|
|
G |
Msn |
moesin |
decreases expression |
EXP |
Bleomycin results in decreased expression of MSN protein |
CTD |
PMID:25933445 |
|
NCBI chr X:65,226,834...65,294,192
Ensembl chr X:65,226,748...65,295,810
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
increases expression multiple interactions |
ISO EXP |
Bleomycin results in increased expression of MUC5AC mRNA Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of MUC5AC mRNA]; Phytochemicals inhibits the reaction [Bleomycin results in increased expression of MUC5AC mRNA] |
CTD |
PMID:18684396 PMID:26093215 |
|
NCBI chr 1:214,725,482...214,756,653
|
|
G |
Mug1 |
murinoglobulin 1 |
increases expression |
EXP |
Bleomycin results in increased expression of PZP protein |
CTD |
PMID:25933445 |
|
NCBI chr 4:154,676,382...154,729,288
Ensembl chr 4:154,391,647...154,729,310
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases response to substance |
ISO |
MYC protein results in increased susceptibility to Bleomycin |
CTD |
PMID:10449034 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Myh11 |
myosin heavy chain 11 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MYH11 protein |
CTD |
PMID:25933445 |
|
NCBI chr10:764,421...859,184
Ensembl chr10:764,421...859,184
|
|
G |
Myh6 |
myosin heavy chain 6 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MYH6 protein |
CTD |
PMID:25933445 |
|
NCBI chr15:33,605,653...33,629,730
Ensembl chr15:33,605,654...33,629,699
|
|
G |
Myl12b |
myosin light chain 12B |
increases expression |
EXP |
Bleomycin results in increased expression of MYL12B protein |
CTD |
PMID:25933445 |
|
NCBI chr 9:119,307,168...119,321,500
Ensembl chr 9:119,307,176...119,321,500
|
|
G |
Myl4 |
myosin, light chain 4 |
decreases expression |
EXP |
Bleomycin results in decreased expression of MYL4 protein |
CTD |
PMID:25933445 |
|
NCBI chr10:92,628,356...92,638,100
Ensembl chr10:92,628,356...92,638,100
|
|
G |
Myl6l |
myosin, light polypeptide 6, alkali, smooth muscle and non-muscle-like |
increases expression |
EXP |
Bleomycin results in increased expression of MYL6L protein |
CTD |
PMID:25933445 |
|
|
|
G |
Myo1c |
myosin 1C |
decreases expression |
EXP |
Bleomycin results in decreased expression of MYO1C protein |
CTD |
PMID:25933445 |
|
NCBI chr10:63,803,311...63,819,614
Ensembl chr10:63,803,309...63,819,614
|
|
G |
Nap1l1 |
nucleosome assembly protein 1-like 1 |
decreases expression |
ISO |
Bleomycin results in decreased expression of NAP1L1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 7:54,213,305...54,237,880
Ensembl chr 7:54,213,319...54,236,625
|
|
G |
Nfatc2 |
nuclear factor of activated T-cells 2 |
multiple interactions increases expression |
ISO |
MIR101-1 mRNA inhibits the reaction [Bleomycin results in increased expression of NFATC2 mRNA] |
CTD |
PMID:28726637 |
|
NCBI chr 3:165,241,750...165,374,644
Ensembl chr 3:165,245,238...165,360,292
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects localization multiple interactions decreases expression increases expression increases phosphorylation |
ISO EXP |
Bleomycin affects the localization of NFE2L2 protein Berberine promotes the reaction [Bleomycin results in increased expression of NFE2L2 protein]; Methylprednisolone inhibits the reaction [Bleomycin results in decreased expression of NFE2L2 mRNA]; Phytochemicals inhibits the reaction [Bleomycin results in decreased expression of NFE2L2 mRNA]; tripterine inhibits the reaction [Bleomycin results in decreased expression of NFE2L2 protein] Bleomycin results in decreased expression of NFE2L2 mRNA; Bleomycin results in decreased expression of NFE2L2 protein caffeic acid phenethyl ester inhibits the reaction [Bleomycin results in decreased expression of NFE2L2 protein]; U 0126 inhibits the reaction [Bleomycin affects the localization of NFE2L2 protein]; U 0126 inhibits the reaction [Bleomycin results in increased phosphorylation of NFE2L2 protein] |
CTD |
PMID:23523906 PMID:23570914 PMID:26093215 PMID:26768587 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases activity multiple interactions increases expression |
ISO EXP |
Bleomycin results in increased activity of NFKB1 protein NOS2 protein affects the reaction [Bleomycin results in increased activity of NFKB1 protein] Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of NFKB1 mRNA]; Phytochemicals inhibits the reaction [Bleomycin results in increased expression of NFKB1 mRNA] |
CTD |
PMID:12003776 PMID:26093215 PMID:26526764 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Bleomycin results in increased phosphorylation of GSK3B protein] inhibits the reaction [GSK3B protein binds to and results in increased stability of NFKBIA protein] |
CTD |
PMID:19429264 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nit2 |
nitrilase family, member 2 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of NIT2 protein |
CTD |
PMID:29733421 |
|
NCBI chr11:45,462,345...45,473,107
Ensembl chr11:45,462,345...45,473,104
|
|
G |
Nmbr |
neuromedin B receptor |
decreases expression |
EXP |
Bleomycin results in decreased expression of NMBR mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 1:8,933,744...8,945,850
Ensembl chr 1:8,933,831...8,944,987
|
|
G |
Nme2 |
NME/NM23 nucleoside diphosphate kinase 2 |
increases expression |
EXP |
Bleomycin results in increased expression of NME2 protein |
CTD |
PMID:25933445 |
|
NCBI chr10:81,648,216...81,653,717
Ensembl chr10:81,648,216...81,653,717
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
ISO EXP |
Bleomycin results in increased expression of NOS2 protein Berberine inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]; Curcumin inhibits the reaction [Bleomycin results in increased expression of NOS2 mRNA]; Curcumin inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of NOS2 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]; Taurine inhibits the reaction [Bleomycin results in increased expression of NOS2 protein] Bleomycin results in increased expression of NOS2 mRNA; Bleomycin results in increased expression of NOS2 protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]; 2-((dimethylamino)methyl)-9-hydroxythieno(2,3-c)isoquinolin-5(4H)-one inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]; NOS2 protein affects the reaction [Bleomycin results in increased activity of NFKB1 protein]; NOS2 protein affects the reaction [Bleomycin results in increased expression of LGALS3 protein]; NOS2 protein affects the reaction [Bleomycin results in increased expression of MMP9 protein]; NOS2 protein affects the reaction [Bleomycin results in increased expression of RETNLA protein]; rosiglitazone inhibits the reaction [Bleomycin results in increased expression of NOS2 protein] |
CTD |
PMID:15684285 PMID:17434272 PMID:19362168 PMID:23523906 PMID:26526764 PMID:27704718 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Npm1 |
nucleophosmin 1 |
increases expression |
EXP |
Bleomycin results in increased expression of NPM1 protein |
CTD |
PMID:25933445 |
|
NCBI chr10:18,080,949...18,091,062
Ensembl chr10:18,080,950...18,090,950
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases activity multiple interactions |
EXP |
Bleomycin results in decreased activity of NQO1 protein tripterine inhibits the reaction [Bleomycin results in decreased activity of NQO1 protein] |
CTD |
PMID:26768587 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of NR3C1 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of NR3C2 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr19:34,408,275...34,761,003
Ensembl chr19:34,448,289...34,752,695
|
|
G |
Nucb2 |
nucleobindin 2 |
increases expression |
EXP |
Bleomycin results in increased expression of NUCB2 protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:185,106,773...185,143,278
Ensembl chr 1:185,104,656...185,143,272
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of OAT protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:204,562,289...204,582,070
Ensembl chr 1:204,562,289...204,582,070
|
|
G |
Ostf1 |
osteoclast stimulating factor 1 |
increases expression |
EXP |
Bleomycin results in increased expression of OSTF1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:234,749,568...234,796,739
Ensembl chr 1:234,749,568...234,796,739
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
increases expression |
EXP |
Bleomycin results in increased expression of P4HB protein |
CTD |
PMID:25933445 |
|
NCBI chr10:109,736,459...109,748,070
Ensembl chr10:109,736,458...109,747,987
|
|
G |
Pabpc1 |
poly(A) binding protein, cytoplasmic 1 |
increases expression |
EXP |
Bleomycin results in increased expression of PABPC1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 7:75,409,581...75,421,874
Ensembl chr 7:75,409,581...75,422,268
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases expression multiple interactions increases cleavage |
ISO EXP |
Bleomycin results in increased expression of PARP1 protein Bleomycin inhibits the reaction [Azacitidine results in increased cleavage of PARP1 protein] Bleomycin results in increased cleavage of PARP1 protein |
CTD |
PMID:15371238 PMID:16317386 PMID:32278510 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pcbp2 |
poly(rC) binding protein 2 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of PCBP2 protein |
CTD |
PMID:29733421 |
|
NCBI chr 7:144,077,901...144,103,723
Ensembl chr 7:144,078,496...144,101,893
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
multiple interactions |
EXP |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of PDIA3 protein |
CTD |
PMID:24478030 |
|
NCBI chr 3:113,376,983...113,400,707
Ensembl chr 3:113,376,983...113,400,707
|
|
G |
Pdlim1 |
PDZ and LIM domain 1 |
increases expression |
EXP |
Bleomycin results in increased expression of PDLIM1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:259,308,326...259,357,006
Ensembl chr 1:259,308,296...259,357,056
|
|
G |
Pdlim5 |
PDZ and LIM domain 5 |
increases expression |
EXP |
Bleomycin results in increased expression of PDLIM5 protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:247,815,214...247,989,198
Ensembl chr 2:247,818,243...247,988,462
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression decreases expression |
ISO |
Bleomycin results in increased expression of PLAU mRNA; Bleomycin results in increased expression of PLAU protein Bleomycin results in decreased expression of PLAU protein |
CTD |
PMID:25648892 |
|
NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
|
|
G |
Pml |
PML nuclear body scaffold |
multiple interactions increases expression |
ISO |
arsenic trioxide inhibits the reaction [Bleomycin results in increased expression of PML protein] |
CTD |
PMID:24762191 |
|
NCBI chr 8:63,002,515...63,034,310
Ensembl chr 8:63,004,870...63,034,226
|
|
G |
Pnp |
purine nucleoside phosphorylase |
decreases expression |
EXP |
Bleomycin results in decreased expression of PNP protein |
CTD |
PMID:25933445 |
|
NCBI chr15:27,875,883...27,883,566
Ensembl chr15:27,875,911...27,883,350
|
|
G |
Podxl |
podocalyxin-like |
decreases expression |
EXP |
Bleomycin results in decreased expression of PODXL protein |
CTD |
PMID:25933445 |
|
NCBI chr 4:58,829,049...58,893,353
Ensembl chr 4:58,829,060...58,893,170
|
|
G |
Polb |
DNA polymerase beta |
decreases response to substance |
ISO |
POLB results in decreased susceptibility to Bleomycin |
CTD |
PMID:21251944 |
|
NCBI chr16:74,237,001...74,260,272
Ensembl chr16:74,237,001...74,260,271
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions decreases response to substance |
ISO |
PPARA protein affects the reaction [Bleomycin results in increased expression of HMOX1 protein]; PPARA protein affects the reaction [Bleomycin results in increased expression of IL1B protein]; PPARA protein affects the reaction [Bleomycin results in increased expression of TNF protein] PPARA protein results in decreased susceptibility to Bleomycin |
CTD |
PMID:16317386 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression multiple interactions |
ISO |
Bleomycin results in decreased expression of PPARG mRNA Berberine inhibits the reaction [Bleomycin binds to PPARG protein] rosiglitazone inhibits the reaction [Bleomycin results in decreased expression of PPARG mRNA] |
CTD |
PMID:19147827 PMID:29408570 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppia |
peptidylprolyl isomerase A |
increases expression |
EXP |
Bleomycin results in increased expression of PPIA protein |
CTD |
PMID:25933445 |
|
NCBI chr14:86,673,775...86,677,443
Ensembl chr14:86,673,775...86,677,443
|
|
G |
Prdx2 |
peroxiredoxin 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of PRDX2 protein |
CTD |
PMID:25933445 |
|
NCBI chr19:26,084,816...26,090,095
Ensembl chr19:26,084,903...26,090,094
|
|
G |
Prdx6 |
peroxiredoxin 6 |
decreases expression |
EXP |
Bleomycin results in decreased expression of PRDX6 protein |
CTD |
PMID:25933445 |
|
NCBI chr13:79,077,567...79,088,113
Ensembl chr13:79,077,033...79,088,127
|
|
G |
Prelp |
proline and arginine rich end leucine rich repeat protein |
decreases expression |
EXP |
Bleomycin results in decreased expression of PRELP protein |
CTD |
PMID:25933445 |
|
NCBI chr13:50,749,526...50,773,934
Ensembl chr13:50,749,514...50,761,355
|
|
G |
Psmd13 |
proteasome 26S subunit, non-ATPase 13 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of PSMD13 protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:213,636,159...213,648,499
Ensembl chr 1:213,636,093...213,648,488
|
|
G |
Psme1 |
proteasome activator subunit 1 |
increases expression |
EXP |
Bleomycin results in increased expression of PSME1 protein |
CTD |
PMID:25933445 |
|
NCBI chr15:34,256,071...34,258,947
Ensembl chr15:34,256,071...34,258,947
|
|
G |
Psme2 |
proteasome activator subunit 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of PSME2 protein |
CTD |
PMID:25933445 |
|
NCBI chr15:34,265,552...34,269,851
Ensembl chr15:34,265,557...34,269,851
|
|
G |
Ptbp1 |
polypyrimidine tract binding protein 1 |
increases expression |
EXP |
Bleomycin results in increased expression of PTBP1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 7:12,663,965...12,673,723
Ensembl chr 7:12,663,965...12,673,718
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions decreases expression |
ISO |
((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) inhibits the reaction [Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN protein] Bleomycin results in decreased expression of PTEN mRNA; Bleomycin results in decreased expression of PTEN protein |
CTD |
PMID:29408570 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
increases expression |
ISO |
Bleomycin results in increased expression of PTGDR mRNA |
CTD |
PMID:20719937 |
|
NCBI chr15:19,195,606...19,196,508
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Bleomycin results in increased expression of PTGS2 mRNA; Bleomycin results in increased expression of PTGS2 protein 2-((dimethylamino)methyl)-9-hydroxythieno(2,3-c)isoquinolin-5(4H)-one inhibits the reaction [Bleomycin results in increased expression of PTGS2 protein]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Bleomycin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:26526764 PMID:27704718 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptms |
parathymosin |
increases expression |
EXP |
Bleomycin results in increased expression of PTMS protein |
CTD |
PMID:25933445 |
|
NCBI chr 4:157,435,371...157,439,507
Ensembl chr 4:157,435,373...157,439,507
|
|
G |
Rab1b |
RAB1B, member RAS oncogene family |
increases expression |
EXP |
Bleomycin results in increased expression of RAB1B protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:220,483,529...220,491,469
Ensembl chr 1:220,480,834...220,491,469
|
|
G |
Ralb |
RAS like proto-oncogene B |
increases expression |
EXP |
Bleomycin results in increased expression of RALB protein |
CTD |
PMID:25933445 |
|
NCBI chr13:35,494,716...35,531,503
Ensembl chr13:35,494,721...35,511,020
|
|
G |
Rap1b |
RAP1B, member of RAS oncogene family |
increases expression |
EXP |
Bleomycin results in increased expression of RAP1B protein |
CTD |
PMID:25933445 |
|
NCBI chr 7:60,850,406...60,878,226
Ensembl chr 7:60,853,930...60,860,990
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases expression increases expression |
ISO EXP |
Calcitriol inhibits the reaction [Bleomycin results in increased expression of RELA protein]; methyl palmitate inhibits the reaction [Bleomycin results in increased expression of RELA protein] Bleomycin results in decreased expression of RELA mRNA Berberine inhibits the reaction [Bleomycin affects the localization of and results in increased expression of RELA protein]; Bleomycin affects the localization of and results in increased expression of RELA protein; thymoquinone inhibits the reaction [Bleomycin results in increased expression of RELA protein] |
CTD |
PMID:21575650 PMID:22982510 PMID:23523906 PMID:26520185 PMID:29720568 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
decreases expression |
ISO |
Bleomycin results in decreased expression of RELB mRNA |
CTD |
PMID:29720568 |
|
NCBI chr 1:80,517,081...80,545,019
Ensembl chr 1:80,517,411...80,544,825
|
|
G |
RGD1562690 |
similar to L-lactate dehydrogenase A chain (LDH-A) (LDH muscle subunit) (LDH-M) |
decreases expression |
EXP |
Bleomycin results in decreased expression of RGD1562690 protein |
CTD |
PMID:25933445 |
|
NCBI chr 8:33,075,109...33,076,725
Ensembl chr 8:33,075,211...33,076,206
|
|
G |
RGD1566085 |
similar to pyridoxal (pyridoxine, vitamin B6) kinase |
increases expression |
EXP |
Bleomycin results in increased expression of PDXK protein |
CTD |
PMID:25933445 |
|
NCBI chr20:10,883,952...10,912,870
Ensembl chr20:10,889,573...10,912,769
|
|
G |
Rpl12 |
ribosomal protein L12 |
increases expression |
EXP |
Bleomycin results in increased expression of RPL12 protein |
CTD |
PMID:25933445 |
|
NCBI chr 3:12,009,578...12,011,952
Ensembl chr 3:12,009,578...12,011,666
|
|
G |
Rpl13 |
ribosomal protein L13 |
increases expression |
EXP |
Bleomycin results in increased expression of RPL13 protein |
CTD |
PMID:25933445 |
|
NCBI chr19:55,917,489...55,920,040
Ensembl chr19:55,917,736...55,919,996
|
|
G |
Rpl4 |
ribosomal protein L4 |
increases expression |
EXP |
Bleomycin results in increased expression of RPL4 protein |
CTD |
PMID:25933445 |
|
NCBI chr 8:69,121,682...69,126,805
Ensembl chr 8:69,121,682...69,126,805
|
|
G |
Rpl5 |
ribosomal protein L5 |
increases expression |
EXP |
Bleomycin results in increased expression of RPL5 protein |
CTD |
PMID:25933445 |
|
NCBI chr14:2,860,963...2,867,397
Ensembl chr14:2,860,965...2,867,397
|
|
G |
Rpl6 |
ribosomal protein L6 |
affects expression |
EXP |
Bleomycin affects the expression of RPL6 protein |
CTD |
PMID:25933445 |
|
NCBI chr12:40,877,578...40,882,032
Ensembl chr12:40,877,613...40,881,124
|
|
G |
Rps3a |
ribosomal protein S3a |
increases expression |
EXP |
Bleomycin results in increased expression of RPS3A1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:185,440,477...185,444,846
Ensembl chr 2:185,440,291...185,444,897
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
increases expression |
EXP |
Bleomycin results in increased expression of S100A11 protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:193,863,185...193,868,646
Ensembl chr 2:193,866,951...193,868,502
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
increases expression multiple interactions |
EXP |
Bleomycin results in increased expression of S100A4 protein andrographolide inhibits the reaction [Bleomycin results in increased expression of S100A4 protein] |
CTD |
PMID:25933445 PMID:31706003 |
|
NCBI chr 2:189,997,278...189,999,587
Ensembl chr 2:189,997,129...189,999,604
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
affects expression |
EXP |
Bleomycin affects the expression of S100A6 protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:190,007,013...190,008,512
Ensembl chr 2:190,007,216...190,008,511
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
increases expression |
EXP |
Bleomycin results in increased expression of S100A8 protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:190,073,239...190,074,333
Ensembl chr 2:190,073,815...190,074,354
|
|
G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
multiple interactions |
ISO |
[S1PR5 protein affects the susceptibility to Bleomycin] which affects the expression of S1PR1 protein |
CTD |
PMID:29033951 |
|
NCBI chr 2:218,654,406...218,658,761
Ensembl chr 2:218,654,554...218,658,761
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
multiple interactions increases expression |
ISO |
S1PR5 protein affects the reaction [Bleomycin results in increased expression of S1PR3 mRNA] |
CTD |
PMID:29033951 |
|
NCBI chr17:13,799,383...13,812,877
Ensembl chr17:13,799,383...13,812,704
|
|
G |
S1pr5 |
sphingosine-1-phosphate receptor 5 |
multiple interactions affects response to substance |
ISO |
[S1PR5 protein affects the susceptibility to Bleomycin] which affects the expression of COMP protein; [S1PR5 protein affects the susceptibility to Bleomycin] which affects the expression of S1PR1 protein; S1PR5 protein affects the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; S1PR5 protein affects the reaction [Bleomycin results in increased expression of GATA3 mRNA]; S1PR5 protein affects the reaction [Bleomycin results in increased expression of S1PR3 mRNA]; S1PR5 protein affects the reaction [Bleomycin results in increased expression of SMAD7 mRNA] |
CTD |
PMID:29033951 |
|
NCBI chr 8:22,268,635...22,273,708
Ensembl chr 8:22,268,657...22,270,647
|
|
G |
Scarna15 |
small Cajal body-specific RNA 15 |
affects expression |
EXP |
Bleomycin affects the expression of SCARNA15 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 1:143,360,224...143,360,287
Ensembl chr 1:143,360,224...143,360,287
|
|
G |
Scgb1a1 |
secretoglobin family 1A member 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of SCGB1A1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:225,279,698...225,283,246
Ensembl chr 1:225,279,676...225,283,326
|
|
G |
Scp2 |
sterol carrier protein 2 |
increases expression |
EXP |
Bleomycin results in increased expression of SCP2 protein |
CTD |
PMID:25933445 |
|
NCBI chr 5:127,647,934...127,735,703
Ensembl chr 5:127,620,274...127,735,739
|
|
G |
Scpep1 |
serine carboxypeptidase 1 |
increases expression |
EXP |
Bleomycin results in increased expression of SCPEP1 protein |
CTD |
PMID:25933445 |
|
NCBI chr10:76,230,371...76,263,866
Ensembl chr10:76,230,373...76,263,866
|
|
G |
Sec14l3 |
SEC14-like lipid binding 3 |
decreases expression |
EXP |
Bleomycin results in decreased expression of SEC14L3 protein |
CTD |
PMID:25933445 |
|
NCBI chr14:84,306,466...84,317,241
Ensembl chr14:84,274,550...84,319,449
|
|
G |
Selenbp1 |
selenium binding protein 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of SELENBP1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:196,105,592...196,146,474
Ensembl chr 2:196,105,569...196,113,149
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
ISO |
Bleomycin results in increased expression of SERPINE1 protein |
CTD |
PMID:29175452 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Serpinh1 |
serpin family H member 1 |
multiple interactions increases expression |
EXP |
allyl sulfide inhibits the reaction [Bleomycin results in increased expression of SERPINH1 protein] |
CTD |
PMID:23656969 PMID:25933445 |
|
NCBI chr 1:164,301,010...164,308,306
Ensembl chr 1:164,301,010...164,308,317
|
|
G |
Sfrp1 |
secreted frizzled-related protein 1 |
increases expression |
ISO |
Bleomycin results in increased expression of SFRP1 mRNA |
CTD |
PMID:26345256 |
|
NCBI chr16:73,372,007...73,410,777
Ensembl chr16:73,372,007...73,410,777
|
|
G |
Sftpa1 |
surfactant protein A1 |
multiple interactions increases expression decreases expression |
ISO EXP |
[Bleomycin co-treated with SFTPA1 protein polymorphism] results in increased expression of CXCL8 protein; [Bleomycin co-treated with SFTPA1 protein polymorphism] results in increased expression of TNF protein; Bleomycin promotes the reaction [[SFTPA1 protein binds to SFTPA2 protein] which results in increased expression of TNF protein]; calfactant inhibits the reaction [Bleomycin promotes the reaction [[SFTPA1 protein binds to SFTPA2 protein] which results in increased expression of TNF protein]] Bleomycin results in increased expression of SFTPA1 protein Bleomycin results in decreased expression of SFTPA1 mRNA |
CTD |
PMID:14617519 PMID:15782499 PMID:25933445 |
|
NCBI chr16:18,716,019...18,719,404
Ensembl chr16:18,716,019...18,719,403
|
|
G |
Sftpb |
surfactant protein B |
decreases expression |
EXP |
Bleomycin results in decreased expression of SFTPB mRNA |
CTD |
PMID:15782499 |
|
NCBI chr 4:100,166,855...100,175,941
Ensembl chr 4:100,166,863...100,175,938
|
|
G |
Sftpd |
surfactant protein D |
increases expression multiple interactions increases metabolic processing |
EXP ISO |
Bleomycin results in increased expression of SFTPD mRNA; Bleomycin results in increased expression of SFTPD protein Bleomycin promotes the reaction [SFTPD protein binds to SFTPD protein binds to SFTPD protein]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Bleomycin results in increased metabolism of SFTPD protein] |
CTD |
PMID:11880309 PMID:25933445 PMID:26526764 |
|
NCBI chr16:18,753,535...18,766,100
Ensembl chr16:18,745,458...18,766,174
|
|
G |
Sirt1 |
sirtuin 1 |
decreases expression multiple interactions |
ISO |
Bleomycin results in decreased expression of SIRT1 mRNA; Bleomycin results in decreased expression of SIRT1 protein resveratrol inhibits the reaction [Bleomycin results in decreased expression of SIRT1 mRNA]; resveratrol inhibits the reaction [Bleomycin results in decreased expression of SIRT1 protein] |
CTD |
PMID:25707573 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Slc12a1 |
solute carrier family 12 member 1 |
increases expression |
EXP |
Bleomycin results in increased expression of SLC12A1 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 3:117,421,531...117,498,372
Ensembl chr 3:117,421,604...117,498,367
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
increases expression |
EXP |
Bleomycin results in increased expression of SLC1A2 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 3:92,518,679...92,665,731
Ensembl chr 3:92,640,752...92,665,644
|
|
G |
Slc25a4 |
solute carrier family 25 member 4 |
decreases expression |
EXP |
Bleomycin results in decreased expression of SLC25A4 protein |
CTD |
PMID:25933445 |
|
NCBI chr16:49,266,903...49,270,698
Ensembl chr16:49,266,903...49,270,698
|
|
G |
Slc25a5 |
solute carrier family 25 member 5 |
decreases expression |
EXP |
Bleomycin results in decreased expression of SLC25A5 protein |
CTD |
PMID:25933445 |
|
NCBI chr X:123,404,570...123,407,637
Ensembl chr X:123,404,518...123,407,645
|
|
G |
Slc6a12 |
solute carrier family 6 member 12 |
increases expression |
EXP |
Bleomycin results in increased expression of SLC6A12 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 4:153,921,199...153,941,333
Ensembl chr 4:153,921,115...153,941,391
|
|
G |
Slc9a3r1 |
SLC9A3 regulator 1 |
increases expression |
EXP |
Bleomycin results in increased expression of SLC9A3R1 protein |
CTD |
PMID:25933445 |
|
NCBI chr10:103,713,045...103,730,145
Ensembl chr10:103,713,045...103,730,145
|
|
G |
Slc9a3r2 |
SLC9A3 regulator 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of SLC9A3R2 protein |
CTD |
PMID:25933445 |
|
NCBI chr10:14,003,330...14,015,066
Ensembl chr10:14,003,320...14,013,870
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Bleomycin inhibits the reaction [SLCO2B1 protein results in increased uptake of Cascade Blue] |
CTD |
PMID:30863990 |
|
NCBI chr 1:164,623,313...164,671,612
Ensembl chr 1:164,623,599...164,671,577
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Bleomycin results in increased expression of SLPI protein |
CTD |
PMID:26345256 |
|
NCBI chr 3:160,799,979...160,802,228
Ensembl chr 3:160,799,981...160,802,433
|
|
G |
Smad2 |
SMAD family member 2 |
increases phosphorylation multiple interactions |
ISO |
Bleomycin results in increased phosphorylation of SMAD2 protein camostat inhibits the reaction [Bleomycin results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:26599507 |
|
NCBI chr18:72,550,107...72,612,078
Ensembl chr18:72,550,219...72,612,078
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions increases phosphorylation increases expression |
EXP ISO |
Phytochemicals inhibits the reaction [Bleomycin results in increased expression of SMAD3 mRNA] Bleomycin results in increased phosphorylation of SMAD3 protein 2-((dimethylamino)methyl)-9-hydroxythieno(2,3-c)isoquinolin-5(4H)-one inhibits the reaction [Bleomycin results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:26093215 PMID:27704718 |
|
NCBI chr 8:68,569,530...68,678,349
Ensembl chr 8:68,569,530...68,678,349
|
|
G |
Smad7 |
SMAD family member 7 |
decreases expression multiple interactions increases expression |
EXP ISO |
Bleomycin results in decreased expression of SMAD7 mRNA S1PR5 protein affects the reaction [Bleomycin results in increased expression of SMAD7 mRNA] |
CTD |
PMID:26093215 PMID:29033951 |
|
NCBI chr18:71,395,830...71,424,164
Ensembl chr18:71,395,830...71,424,157
|
|
G |
Smc1a |
structural maintenance of chromosomes 1A |
increases phosphorylation |
ISO |
Bleomycin results in increased phosphorylation of SMC1A protein |
CTD |
PMID:24933654 |
|
NCBI chr X:21,710,976...21,755,708
Ensembl chr X:21,711,019...21,755,525
|
|
G |
Snora58 |
small nucleolar RNA, H/ACA box 58 |
decreases expression |
EXP |
Bleomycin results in decreased expression of SNORA58 mRNA |
CTD |
PMID:25933445 |
|
NCBI chr 6:111,468,732...111,468,807
Ensembl chr 6:111,468,732...111,468,807
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
decreases expression |
ISO |
Bleomycin results in decreased expression of SOCS1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:4,956,795...4,958,472
Ensembl chr10:4,957,326...4,958,461
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression decreases expression multiple interactions |
ISO EXP |
Bleomycin results in increased expression of SOD1 protein Bleomycin results in decreased expression of SOD1 protein IL1A protein promotes the reaction [Bleomycin results in increased expression of SOD1 protein]; IL1B protein promotes the reaction [Bleomycin results in increased expression of SOD1 protein]; TNF protein promotes the reaction [Bleomycin results in increased expression of SOD1 protein] |
CTD |
PMID:8317554 PMID:25933445 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression multiple interactions decreases activity |
ISO EXP |
Bleomycin results in increased expression of SOD2 protein tripterine inhibits the reaction [Bleomycin results in decreased activity of SOD2 protein] IL1A protein promotes the reaction [Bleomycin results in increased expression of SOD2 protein]; IL1B protein promotes the reaction [Bleomycin results in increased expression of SOD2 protein]; TNF protein promotes the reaction [Bleomycin results in increased expression of SOD2 protein] |
CTD |
PMID:8317554 PMID:26768587 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
increases response to substance |
ISO |
SPARC protein results in increased susceptibility to Bleomycin |
CTD |
PMID:19446018 |
|
NCBI chr10:40,742,390...40,764,232
Ensembl chr10:40,742,400...40,764,185
|
|
G |
Sparcl1 |
SPARC like 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of SPARCL1 protein |
CTD |
PMID:25933445 |
|
NCBI chr14:6,994,261...7,025,309
Ensembl chr14:6,994,190...7,025,308
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
Bleomycin results in increased expression of SPP1 mRNA; Bleomycin results in increased expression of SPP1 protein |
CTD |
PMID:26345256 PMID:29175452 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of SPTAN1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 3:8,534,437...8,599,259
Ensembl chr 3:8,534,440...8,599,260
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
ISO |
Bleomycin results in increased expression of SRXN1 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 3:147,608,850...147,614,410
Ensembl chr 3:147,609,095...147,632,801
|
|
G |
Sstr1 |
somatostatin receptor 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of SSTR1 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 6:79,252,914...79,258,611
Ensembl chr 6:79,254,339...79,258,611
|
|
G |
Sstr2 |
somatostatin receptor 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of SSTR2 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr10:102,136,283...102,143,449
Ensembl chr10:102,136,283...102,143,434
|
|
G |
Sstr3 |
somatostatin receptor 3 |
decreases expression |
EXP |
Bleomycin results in decreased expression of SSTR3 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 7:119,760,881...119,768,082
Ensembl chr 7:119,760,888...119,768,082
|
|
G |
St14 |
ST14 transmembrane serine protease matriptase |
multiple interactions |
ISO |
Bleomycin results in increased expression of and results in increased activity of ST14 protein |
CTD |
PMID:26599507 |
|
NCBI chr 8:32,240,113...32,280,813
Ensembl chr 8:32,240,133...32,280,869
|
|
G |
Stat6 |
signal transducer and activator of transcription 6 |
multiple interactions decreases response to substance |
ISO |
STAT6 protein affects the reaction [Bleomycin results in increased expression of RETNLA mRNA] STAT6 gene mutant form results in decreased susceptibility to Bleomycin |
CTD |
PMID:15322207 |
|
NCBI chr 7:70,946,228...70,963,542
Ensembl chr 7:70,946,228...70,964,484
|
|
G |
Stk11 |
serine/threonine kinase 11 |
increases expression multiple interactions |
ISO |
Bleomycin results in increased expression of STK11 protein Soot inhibits the reaction [Bleomycin results in increased expression of STK11 protein] |
CTD |
PMID:31302203 |
|
NCBI chr 7:12,440,751...12,457,513
Ensembl chr 7:12,440,751...12,457,513
|
|
G |
Stmn1 |
stathmin 1 |
increases expression |
EXP |
Bleomycin results in increased expression of STMN1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 5:152,680,412...152,686,807
Ensembl chr 5:152,680,407...152,686,806
|
|
G |
Sv2b |
synaptic vesicle glycoprotein 2b |
increases expression |
EXP |
Bleomycin results in increased expression of SV2B mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 1:136,664,199...136,842,247
Ensembl chr 1:136,664,204...136,842,247
|
|
G |
Tacr2 |
tachykinin receptor 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of TACR2 mRNA |
CTD |
PMID:15808516 |
|
NCBI chr20:31,892,515...31,905,153
Ensembl chr20:31,892,515...31,905,153
|
|
G |
Tagln |
transgelin |
increases expression |
EXP |
Bleomycin results in increased expression of TAGLN protein |
CTD |
PMID:25933445 |
|
NCBI chr 8:50,222,895...50,228,369
Ensembl chr 8:50,222,896...50,231,357
|
|
G |
Tagln2 |
transgelin 2 |
increases expression |
EXP |
Bleomycin results in increased expression of TAGLN2 protein |
CTD |
PMID:25933445 |
|
NCBI chr13:90,807,196...90,814,119
Ensembl chr13:90,807,199...90,814,119
|
|
G |
Taldo1 |
transaldolase 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of TALDO1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:214,375,555...214,385,886
Ensembl chr 1:214,375,515...214,385,885
|
|
G |
Tbx21 |
T-box transcription factor 21 |
increases expression |
ISO |
Bleomycin results in increased expression of TBX21 mRNA |
CTD |
PMID:29033951 |
|
NCBI chr10:85,032,799...85,049,331
Ensembl chr10:85,032,799...85,049,331
|
|
G |
Tcp1 |
t-complex 1 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of TCP1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:48,025,664...48,033,343
Ensembl chr 1:48,025,663...48,033,396
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases response to substance |
ISO |
TERT gene mutant form results in decreased susceptibility to Bleomycin |
CTD |
PMID:18008008 |
|
NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
|
|
G |
Tf |
transferrin |
increases expression |
EXP |
Bleomycin results in increased expression of TF protein |
CTD |
PMID:25933445 |
|
NCBI chr 8:111,694,570...111,721,275
Ensembl chr 8:111,673,547...111,721,333
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression increases secretion |
ISO EXP |
12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; 12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; 2-((dimethylamino)methyl)-9-hydroxythieno(2,3-c)isoquinolin-5(4H)-one inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Calcitriol inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; camostat inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; CCL11 protein promotes the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; CCR2 gene mutant form inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; CEBPB protein affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Grape Seed Extract inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide promotes the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Rosiglitazone inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; SPL-334 inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Win 55212-2 inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA] Bleomycin results in increased expression of TGFB1 mRNA; Bleomycin results in increased expression of TGFB1 protein Bleomycin results in increased secretion of TGFB1 protein andrographolide inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; angiotensin I (1-7) inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Berberine inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Curcumin inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Curcumin inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Phytochemicals inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Resveratrol inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Valsartan inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein] |
CTD |
PMID:14609568 PMID:15541506 PMID:16115399 PMID:16314464 PMID:17035056 PMID:17177178 PMID:17434272 PMID:19080365 PMID:19112509 PMID:19147827 PMID:20581171 PMID:22687607 PMID:23523906 PMID:26093215 PMID:26209236 PMID:26520185 PMID:26526764 PMID:26599507 PMID:27704718 PMID:28300665 PMID:28434932 PMID:28694203 PMID:29033951 PMID:29720568 PMID:31706003 PMID:31901889 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tgfb1i1 |
transforming growth factor beta 1 induced transcript 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of TGFB1I1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 1:199,664,039...199,670,970
Ensembl chr 1:199,664,173...199,670,961
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
multiple interactions |
ISO |
[CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA] |
CTD |
PMID:28434932 |
|
NCBI chr13:105,039,639...105,142,010
Ensembl chr13:105,039,853...105,141,030
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
increases expression multiple interactions |
ISO |
Bleomycin results in increased expression of TGFB3 mRNA CCL12 protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]]; Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]; HIF1A protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]]; MMP3 protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]] |
CTD |
PMID:28434932 |
|
NCBI chr 6:109,913,757...109,936,217
Ensembl chr 6:109,913,757...109,935,533
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
multiple interactions increases expression |
ISO |
[CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA] MIR101-1 mRNA inhibits the reaction [Bleomycin results in increased expression of TGFBR1 mRNA] |
CTD |
PMID:28434932 PMID:28726637 |
|
NCBI chr 5:63,056,071...63,119,635
Ensembl chr 5:63,050,758...63,119,635
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
multiple interactions |
ISO |
[CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA] |
CTD |
PMID:28434932 |
|
NCBI chr 8:124,310,288...124,399,345
Ensembl chr 8:124,312,754...124,399,494
|
|
G |
Thbs1 |
thrombospondin 1 |
increases expression |
ISO |
Bleomycin results in increased expression of THBS1 mRNA |
CTD |
PMID:29720568 |
|
NCBI chr 3:109,862,120...109,873,466
Ensembl chr 3:109,862,117...109,873,466
|
|
G |
Thop1 |
thimet oligopeptidase 1 |
decreases expression |
ISO |
Bleomycin results in decreased expression of THOP1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 7:11,501,145...11,513,576
Ensembl chr 7:11,501,146...11,513,581
|
|
G |
Thrb |
thyroid hormone receptor beta |
decreases expression |
EXP |
Bleomycin results in decreased expression of THRB mRNA |
CTD |
PMID:15808516 |
|
NCBI chr15:8,890,578...9,239,815
Ensembl chr15:8,890,578...9,086,282
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO |
Bleomycin results in increased expression of TIMP1 mRNA; Bleomycin results in increased expression of TIMP1 protein Dexamethasone inhibits the reaction [Bleomycin results in increased expression of TIMP1 protein]; Grape Seed Extract inhibits the reaction [Bleomycin results in increased expression of TIMP1 protein] |
CTD |
PMID:26345256 PMID:28300665 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tlr1 |
toll-like receptor 1 |
decreases expression |
ISO |
Bleomycin results in decreased expression of TLR1 mRNA |
CTD |
PMID:29720568 |
|
NCBI chr14:45,062,662...45,065,014
Ensembl chr14:45,062,662...45,081,991
|
|
G |
Tnc |
tenascin C |
increases expression |
ISO |
Bleomycin results in increased expression of TNC mRNA; Bleomycin results in increased expression of TNC protein |
CTD |
PMID:26345256 |
|
NCBI chr 5:79,789,686...79,874,555
Ensembl chr 5:79,789,671...79,874,671
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression increases secretion |
ISO EXP |
[Bleomycin co-treated with SFTPA1 protein polymorphism] results in increased expression of TNF protein; [Bleomycin co-treated with SFTPA2 protein polymorphism] results in increased expression of TNF protein; Bleomycin promotes the reaction [[SFTPA1 protein binds to SFTPA2 protein] which results in increased expression of TNF protein]; calfactant inhibits the reaction [Bleomycin promotes the reaction [[SFTPA1 protein binds to SFTPA2 protein] which results in increased expression of TNF protein]]; Ozone inhibits the reaction [[Bleomycin co-treated with SFTPA2 protein polymorphism] results in increased expression of TNF protein]; TNF protein promotes the reaction [Bleomycin results in increased expression of CAT protein]; TNF protein promotes the reaction [Bleomycin results in increased expression of SOD1 protein]; TNF protein promotes the reaction [Bleomycin results in increased expression of SOD2 protein] Bleomycin results in increased expression of TNF mRNA Bleomycin results in increased expression of TNF mRNA; Bleomycin results in increased expression of TNF protein Bleomycin results in increased secretion of TNF protein Berberine inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; Phytochemicals inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; resveratrol inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Taurine inhibits the reaction [Bleomycin results in increased expression of TNF protein]; tripterine inhibits the reaction [Bleomycin results in increased expression of TNF protein] 2-((dimethylamino)methyl)-9-hydroxythieno(2,3-c)isoquinolin-5(4H)-one inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Calcitriol inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; CCR2 gene mutant form inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; CEBPB protein affects the reaction [Bleomycin results in increased expression of TNF mRNA]; Enalapril inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; Oils, Volatile inhibits the reaction [Bleomycin results in increased expression of TNF protein]; pirinixic acid inhibits the reaction [Bleomycin results in increased expression of TNF protein]; PPARA protein affects the reaction [Bleomycin results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of TNF protein]; tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; TRPM2 gene mutant form inhibits the reaction [Bleomycin results in increased secretion of TNF protein]; verlukast inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Win 55212-2 inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; zileuton inhibits the reaction [Bleomycin results in increased expression of TNF protein] |
CTD |
PMID:8317554 PMID:8473757 PMID:11350791 PMID:12003776 PMID:14609568 PMID:14617519 PMID:15541506 PMID:16317386 PMID:17035056 PMID:17118201 PMID:17177178 PMID:19080365 PMID:19362168 PMID:22687607 PMID:23523906 PMID:26093215 PMID:26520185 PMID:26600069 PMID:26768587 PMID:27704718 PMID:28850077 PMID:31901889 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases response to substance |
ISO |
TNFRSF1A results in increased susceptibility to Bleomycin |
CTD |
PMID:12003776 |
|
NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
increases expression increases response to substance |
EXP ISO |
Bleomycin results in increased expression of TNFRSF1B protein TNFRSF1B results in increased susceptibility to Bleomycin |
CTD |
PMID:12003776 PMID:15371238 |
|
NCBI chr 5:163,136,390...163,167,299
Ensembl chr 5:163,136,390...163,167,299
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases expression |
ISO |
Bleomycin results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:29720568 |
|
NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions increases phosphorylation increases response to substance |
ISO |
Bleomycin results in increased expression of TRP53 protein Bleomycin results in increased expression of TP53 mRNA 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Bleomycin promotes the reaction [Resveratrol results in increased phosphorylation of TP53 protein]]; 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Bleomycin results in increased phosphorylation of TP53 protein]; 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Resveratrol promotes the reaction [Bleomycin results in increased phosphorylation of TP53 protein]]; Bleomycin promotes the reaction [Polyphenols results in increased expression of TP53 mRNA]; Bleomycin promotes the reaction [Resveratrol results in increased phosphorylation of TP53 protein]; Bleomycin promotes the reaction [Tea results in increased expression of TP53 mRNA]; Polyphenols promotes the reaction [Bleomycin results in increased expression of TP53 mRNA]; Resveratrol promotes the reaction [Bleomycin results in increased phosphorylation of TP53 protein]; Tea promotes the reaction [Bleomycin results in increased expression of TP53 mRNA] TP53 protein results in increased susceptibility to Bleomycin |
CTD |
PMID:9683175 PMID:20135637 PMID:24933654 PMID:26800624 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tpm1 |
tropomyosin 1 |
increases expression |
EXP |
Bleomycin results in increased expression of TPM1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 8:72,814,737...72,841,496
Ensembl chr 8:72,814,740...72,842,228
|
|
G |
Tpm3 |
tropomyosin 3 |
increases expression |
EXP |
Bleomycin results in increased expression of TPM3 protein |
CTD |
PMID:25933445 |
|
NCBI chr 2:189,423,534...189,451,340
Ensembl chr 2:189,423,559...189,451,029
|
|
G |
Tpm4 |
tropomyosin 4 |
increases expression |
EXP |
Bleomycin results in increased expression of TPM4 protein |
CTD |
PMID:25933445 |
|
NCBI chr16:19,385,810...19,399,851
Ensembl chr16:19,385,736...19,399,903
|
|
G |
Tppp3 |
tubulin polymerization-promoting protein family member 3 |
decreases expression |
EXP |
Bleomycin results in decreased expression of TPPP3 protein |
CTD |
PMID:25933445 |
|
NCBI chr19:37,424,323...37,428,075
Ensembl chr19:37,424,324...37,427,989
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
decreases expression |
EXP |
Bleomycin results in decreased expression of TRAF2 protein |
CTD |
PMID:15371238 |
|
NCBI chr 3:2,746,061...2,770,690
Ensembl chr 3:2,746,075...2,770,620
|
|
G |
Traf3ip2 |
Traf3 interacting protein 2 |
multiple interactions |
ISO |
Calcitriol inhibits the reaction [Bleomycin results in increased phosphorylation of ACT1 protein] |
CTD |
PMID:26520185 |
|
NCBI chr20:44,679,861...44,722,874
Ensembl chr20:44,680,449...44,722,872
|
|
G |
Trim28 |
tripartite motif-containing 28 |
increases phosphorylation |
ISO |
Bleomycin results in increased phosphorylation of TRIM28 protein |
CTD |
PMID:24933654 |
|
NCBI chr 1:65,544,369...65,551,043
Ensembl chr 1:65,544,373...65,551,043
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
multiple interactions |
ISO |
TRPM2 gene mutant form inhibits the reaction [Bleomycin results in increased secretion of CXCL1 protein]; TRPM2 gene mutant form inhibits the reaction [Bleomycin results in increased secretion of CXCL2 protein]; TRPM2 gene mutant form inhibits the reaction [Bleomycin results in increased secretion of IL1B protein]; TRPM2 gene mutant form inhibits the reaction [Bleomycin results in increased secretion of TNF protein] |
CTD |
PMID:26600069 |
|
NCBI chr20:11,434,062...11,482,880
Ensembl chr20:11,436,267...11,482,051
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
decreases expression |
EXP |
Bleomycin results in decreased expression of TSHR mRNA |
CTD |
PMID:15808516 |
|
NCBI chr 6:115,170,290...115,306,871
Ensembl chr 6:115,170,865...115,306,871
|
|
G |
Tuba1c |
tubulin, alpha 1C |
decreases expression |
EXP |
Bleomycin results in decreased expression of TUBA1C protein |
CTD |
PMID:25933445 |
|
NCBI chr 7:140,716,113...140,723,717
Ensembl chr 7:140,716,113...140,723,714
|
|
G |
Tubb2a |
tubulin, beta 2A class IIa |
decreases expression |
EXP |
Bleomycin results in decreased expression of TUBB2A protein |
CTD |
PMID:25933445 |
|
NCBI chr17:31,493,145...31,496,827
Ensembl chr17:31,493,107...31,498,651
|
|
G |
Tubb4b |
tubulin, beta 4B class IVb |
decreases expression |
EXP |
Bleomycin results in decreased expression of TUBB4B protein |
CTD |
PMID:25933445 |
|
NCBI chr 3:2,441,585...2,444,369
Ensembl chr 3:2,441,733...2,444,281
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
increases expression multiple interactions |
ISO |
Bleomycin results in increased expression of ULK1 protein modified form Soot inhibits the reaction [Bleomycin results in increased expression of ULK1 protein modified form] |
CTD |
PMID:31302203 |
|
NCBI chr12:51,908,105...51,934,704
Ensembl chr12:51,908,448...51,934,702
|
|
G |
Uqcrc1 |
ubiquinol-cytochrome c reductase core protein 1 |
decreases expression |
EXP |
Bleomycin results in decreased expression of UQCRC1 protein |
CTD |
PMID:25933445 |
|
NCBI chr 8:117,679,328...117,691,073
Ensembl chr 8:117,679,278...117,691,071
|
|
G |
Uqcrh |
ubiquinol-cytochrome c reductase hinge protein |
increases expression |
EXP |
Bleomycin results in increased expression of UQCRHL protein |
CTD |
PMID:25933445 |
|
NCBI chr 5:134,919,040...134,927,235
Ensembl chr 5:134,919,044...134,927,235
|
|
G |
Vcl |
vinculin |
decreases expression |
EXP |
Bleomycin results in decreased expression of VCL protein |
CTD |
PMID:25933445 |
|
NCBI chr15:3,455,211...3,544,738
Ensembl chr15:3,455,211...3,544,702
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
EXP |
Bleomycin results in increased expression of VEGFA mRNA |
CTD |
PMID:26093215 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vim |
vimentin |
increases expression |
EXP |
Bleomycin results in increased expression of VIM protein |
CTD |
PMID:25933445 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
affects response to substance decreases response to substance |
ISO |
XRCC1 gene polymorphism affects the susceptibility to Bleomycin XRCC1 results in decreased susceptibility to Bleomycin |
CTD |
PMID:12082022 PMID:20705543 |
|
NCBI chr 1:81,412,635...81,441,680
Ensembl chr 1:81,413,353...81,441,678
|
|
G |
Xrcc5 |
X-ray repair cross complementing 5 |
affects response to substance |
ISO |
XRCC5 protein affects the susceptibility to Bleomycin |
CTD |
PMID:12384553 |
|
NCBI chr 9:79,659,275...79,748,050
Ensembl chr 9:79,659,251...79,748,078
|
|
G |
Ywhab |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta |
decreases expression |
EXP |
Bleomycin results in decreased expression of YWHAB protein |
CTD |
PMID:25933445 |
|
NCBI chr 3:160,391,108...160,399,931
Ensembl chr 3:160,391,106...160,399,931
|
|
|
G |
Abhd10 |
abhydrolase domain containing 10, depalmitoylase |
decreases expression |
ISO |
bleomycetin results in decreased expression of ABHD10 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr11:60,053,719...60,068,142
Ensembl chr11:60,054,408...60,066,739
|
|
G |
Alg12 |
ALG12, alpha-1,6-mannosyltransferase |
decreases expression |
ISO |
bleomycetin results in decreased expression of ALG12 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 7:129,798,663...129,812,677
Ensembl chr 7:129,798,663...129,812,388
|
|
G |
Amacr |
alpha-methylacyl-CoA racemase |
decreases expression |
ISO |
bleomycetin results in decreased expression of AMACR mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 2:60,949,276...60,961,342
Ensembl chr 2:60,949,256...60,961,326
|
|
G |
Arf4 |
ADP-ribosylation factor 4 |
decreases expression |
ISO |
bleomycetin results in decreased expression of ARF4 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr16:2,338,333...2,354,909
Ensembl chr16:2,338,333...2,354,909
|
|
G |
B2m |
beta-2 microglobulin |
decreases expression |
ISO |
bleomycetin results in decreased expression of B2M mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 3:114,087,287...114,093,311
Ensembl chr 3:114,087,287...114,093,309
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases expression |
ISO |
bleomycetin results in increased expression of BMP2 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
|
|
G |
Ca9 |
carbonic anhydrase 9 |
increases expression multiple interactions decreases response to substance |
ISO |
bleomycetin results in increased expression of CA9 mRNA; bleomycetin results in increased expression of CA9 protein CA9 protein inhibits the reaction [bleomycetin results in increased activity of CASP3 protein] CA9 protein results in decreased susceptibility to bleomycetin |
CTD |
PMID:21040473 |
|
NCBI chr 5:59,008,277...59,015,535
Ensembl chr 5:59,008,933...59,015,528
|
|
G |
Casd1 |
CAS1 domain containing 1 |
decreases expression |
ISO |
bleomycetin results in decreased expression of CASD1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 4:29,638,280...29,693,151
Ensembl chr 4:29,639,154...29,691,928
|
|
G |
Casp1 |
caspase 1 |
decreases expression |
ISO |
bleomycetin results in decreased expression of CASP1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Acetazolamide promotes the reaction [bleomycetin results in increased activity of CASP3 protein]; CA9 protein inhibits the reaction [bleomycetin results in increased activity of CASP3 protein] |
CTD |
PMID:21040473 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cdhr5 |
cadherin-related family member 5 |
decreases expression |
ISO |
bleomycetin results in decreased expression of CDHR5 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 1:214,255,118...214,263,848
Ensembl chr 1:214,255,110...214,263,581
|
|
G |
Cox7b |
cytochrome c oxidase subunit 7B |
decreases expression |
ISO |
bleomycetin results in decreased expression of COX7B mRNA |
CTD |
PMID:21040473 |
|
NCBI chr X:77,065,427...77,071,676
Ensembl chr X:77,065,397...77,071,676
|
|
G |
Cul4a |
cullin 4A |
increases expression |
ISO |
bleomycetin results in increased expression of CUL4A mRNA |
CTD |
PMID:21040473 |
|
NCBI chr16:81,718,784...81,756,653
Ensembl chr16:81,719,028...81,756,654
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
bleomycetin results in increased expression of DDIT4 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
decreases expression |
ISO |
bleomycetin results in decreased expression of DHCR24 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 5:126,164,708...126,188,926
Ensembl chr 5:126,164,674...126,191,206
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
decreases expression |
ISO |
bleomycetin results in decreased expression of DKK1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 1:248,952,896...248,956,579
Ensembl chr 1:248,895,738...248,898,607
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
decreases expression |
ISO |
bleomycetin results in decreased expression of DPYSL2 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr15:43,475,640...43,581,725
Ensembl chr15:43,477,629...43,542,939
|
|
G |
Ehd4 |
EH-domain containing 4 |
increases expression |
ISO |
bleomycetin results in increased expression of EHD4 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 3:111,877,853...111,941,841
Ensembl chr 3:111,877,853...111,941,841
|
|
G |
Eif4g1 |
eukaryotic translation initiation factor 4 gamma, 1 |
increases expression |
ISO |
bleomycetin results in increased expression of EIF4G1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr11:83,907,659...83,927,683
Ensembl chr11:83,908,109...83,926,524
|
|
G |
Emc4 |
ER membrane protein complex subunit 4 |
decreases expression |
ISO |
bleomycetin results in decreased expression of EMC4 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 3:103,852,139...103,857,172
Ensembl chr 3:103,852,139...103,857,158
|
|
G |
Emc7 |
ER membrane protein complex subunit 7 |
decreases expression |
ISO |
bleomycetin results in decreased expression of EMC7 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 3:103,945,276...103,955,970
Ensembl chr 3:103,945,329...103,956,007
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
bleomycetin results in increased expression of ENO2 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
Fbn2 |
fibrillin 2 |
decreases expression |
ISO |
bleomycetin results in decreased expression of FBN2 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr18:53,068,495...53,272,254
Ensembl chr18:53,068,495...53,181,503
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
increases expression |
ISO |
bleomycetin results in increased expression of FKBP1A mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 3:147,042,944...147,062,725
Ensembl chr 3:147,042,944...147,062,724
|
|
G |
Fkbp9 |
FKBP prolyl isomerase 9 |
decreases expression |
ISO |
bleomycetin results in decreased expression of FKBP9 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 4:87,167,514...87,234,198
Ensembl chr 4:87,167,514...87,234,197
|
|
G |
Frs3 |
fibroblast growth factor receptor substrate 3 |
increases expression |
ISO |
bleomycetin results in increased expression of FRS3 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 9:15,297,794...15,306,850
Ensembl chr 9:15,297,895...15,306,465
|
|
G |
Galnt10 |
polypeptide N-acetylgalactosaminyltransferase 10 |
decreases expression |
ISO |
bleomycetin results in decreased expression of GALNT10 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr10:43,067,316...43,208,992
Ensembl chr10:43,067,299...43,210,427
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
bleomycetin results in increased expression of GCLC mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gng11 |
G protein subunit gamma 11 |
decreases expression |
ISO |
bleomycetin results in decreased expression of GNG11 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 4:28,989,170...28,994,610
Ensembl chr 4:28,989,115...28,993,621
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
decreases expression |
ISO |
bleomycetin results in decreased expression of GSTK1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 4:71,621,777...71,626,096
Ensembl chr 4:71,621,729...71,626,107
|
|
G |
H2bc12 |
H2B clustered histone 12 |
decreases expression |
ISO |
bleomycetin results in decreased expression of H2BC12 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr17:44,527,421...44,527,801
Ensembl chr17:44,527,421...44,527,801
|
|
G |
Hnrnpab |
heterogeneous nuclear ribonucleoprotein A/B |
increases expression |
ISO |
bleomycetin results in increased expression of HNRNPAB mRNA |
CTD |
PMID:21040473 |
|
NCBI chr10:34,955,713...34,961,662
Ensembl chr10:34,955,716...34,961,608
|
|
G |
Hoxb7 |
homeo box B7 |
decreases expression |
ISO |
bleomycetin results in decreased expression of HOXB7 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr10:84,135,224...84,138,642
Ensembl chr10:84,135,116...84,138,637
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
decreases expression |
ISO |
bleomycetin results in decreased expression of HSPH1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
decreases expression |
ISO |
bleomycetin results in decreased expression of IDH3A mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 8:59,164,601...59,183,899
Ensembl chr 8:59,164,572...59,183,908
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
decreases expression |
ISO |
bleomycetin results in decreased expression of IDI1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr17:57,976,266...57,984,036
Ensembl chr17:57,976,268...57,984,036
|
|
G |
Itga5 |
integrin subunit alpha 5 |
increases expression |
ISO |
bleomycetin results in increased expression of ITGA5 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 7:144,970,444...144,993,652
Ensembl chr 7:144,970,444...144,993,652
|
|
G |
Itgb5 |
integrin subunit beta 5 |
increases expression |
ISO |
bleomycetin results in increased expression of ITGB5 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr11:70,056,500...70,172,164
Ensembl chr11:70,056,500...70,172,372
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
increases expression |
ISO |
bleomycetin results in increased expression of ITPR1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 4:140,247,297...140,580,749
Ensembl chr 4:140,247,313...140,580,748
|
|
G |
Kat6b |
lysine acetyltransferase 6B |
decreases expression |
ISO |
bleomycetin results in decreased expression of KAT6B mRNA |
CTD |
PMID:21040473 |
|
NCBI chr15:2,811,933...2,966,833
Ensembl chr15:2,813,537...2,966,576
|
|
G |
Lypd3 |
Ly6/Plaur domain containing 3 |
increases expression |
ISO |
bleomycetin results in increased expression of LYPD3 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 1:81,499,856...81,504,306
Ensembl chr 1:81,499,821...81,504,318
|
|
G |
Mageb2 |
MAGE family member B2 |
decreases expression |
ISO |
bleomycetin results in decreased expression of MAGEB2 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr X:54,804,987...54,806,956
|
|
G |
Man1b1 |
mannosidase, alpha, class 1B, member 1 |
increases expression |
ISO |
bleomycetin results in increased expression of MAN1B1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 3:2,547,259...2,569,051
Ensembl chr 3:2,547,986...2,569,049
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
increases expression |
ISO |
bleomycetin results in increased expression of MCM2 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 4:120,825,699...120,840,221
Ensembl chr 4:120,825,699...120,840,111
|
|
G |
Med11 |
mediator complex subunit 11 |
decreases expression |
ISO |
bleomycetin results in decreased expression of MED11 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr10:57,057,272...57,059,415
Ensembl chr10:57,057,608...57,059,403
|
|
G |
Metrn |
meteorin, glial cell differentiation regulator |
increases expression |
ISO |
bleomycetin results in increased expression of METRN mRNA |
CTD |
PMID:21040473 |
|
NCBI chr10:15,164,439...15,166,457
Ensembl chr10:15,164,439...15,166,457
|
|
G |
Mt2A |
metallothionein 2A |
increases expression |
ISO |
bleomycetin results in increased expression of MT2A mRNA; bleomycetin results in increased expression of MT2A protein |
CTD |
PMID:21040473 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
ISO |
bleomycetin results in increased expression of MYC mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Ncbp2 |
nuclear cap binding protein subunit 2 |
increases expression |
ISO |
bleomycetin results in increased expression of NCBP2 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr11:72,071,838...72,103,087
Ensembl chr11:72,921,282...72,929,003
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
increases expression |
ISO |
bleomycetin results in increased expression of NDRG1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 7:107,734,326...107,775,701
Ensembl chr 7:107,734,323...107,775,714
|
|
G |
Nop10 |
NOP10 ribonucleoprotein |
decreases expression |
ISO |
bleomycetin results in decreased expression of NOLA3 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 3:103,747,654...103,748,739
Ensembl chr 3:103,747,654...103,748,739
|
|
G |
Nop56 |
NOP56 ribonucleoprotein |
increases expression |
ISO |
bleomycetin results in increased expression of NOP56 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 3:122,803,726...122,808,564
Ensembl chr 3:122,803,772...122,808,558
|
|
G |
Nrdc |
nardilysin convertase |
decreases expression |
ISO |
bleomycetin results in decreased expression of NRDC mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 5:128,629,949...128,694,209
Ensembl chr 5:128,629,942...128,694,060
|
|
G |
P4ha1 |
prolyl 4-hydroxylase subunit alpha 1 |
increases expression |
ISO |
bleomycetin results in increased expression of P4HA1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr20:28,920,616...28,972,576
Ensembl chr20:28,920,616...28,971,966
|
|
G |
Parn |
poly(A)-specific ribonuclease |
increases expression |
ISO |
bleomycetin results in increased expression of PARN mRNA |
CTD |
PMID:21040473 |
|
NCBI chr10:1,309,724...1,461,123
Ensembl chr10:1,308,414...1,461,269
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
decreases expression |
ISO |
bleomycetin results in decreased expression of PDGFA mRNA |
CTD |
PMID:21040473 |
|
NCBI chr12:17,734,141...17,756,186
Ensembl chr12:17,734,133...17,755,285
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases expression |
ISO |
bleomycetin results in decreased expression of PGD mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 5:165,966,128...165,982,327
|
|
G |
Pgrmc2 |
progesterone receptor membrane component 2 |
increases expression |
ISO |
bleomycetin results in increased expression of PGRMC2 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 2:127,986,106...128,002,005
Ensembl chr 2:127,986,109...128,002,005
|
|
G |
Pkn3 |
protein kinase N3 |
decreases expression |
ISO |
bleomycetin results in decreased expression of PKN3 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 3:8,628,033...8,656,464
Ensembl chr 3:8,628,033...8,659,117
|
|
G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
increases expression |
ISO |
bleomycetin results in increased expression of PPP2R2B mRNA |
CTD |
PMID:21040473 |
|
NCBI chr18:36,985,709...37,421,383
Ensembl chr18:36,985,714...37,245,809
|
|
G |
Pqbp1 |
polyglutamine binding protein 1 |
decreases expression |
ISO |
bleomycetin results in decreased expression of PQBP1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr X:15,448,570...15,453,130
Ensembl chr X:15,348,138...15,453,130
|
|
G |
Ptges |
prostaglandin E synthase |
decreases expression |
ISO |
bleomycetin results in decreased expression of PTGES mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 3:9,727,408...9,738,752
Ensembl chr 3:9,727,408...9,738,752
|
|
G |
Rab31 |
RAB31, member RAS oncogene family |
increases expression |
ISO |
bleomycetin results in increased expression of RAB31 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 9:113,370,072...113,504,606
Ensembl chr 9:113,370,033...113,504,605
|
|
G |
Rbp4 |
retinol binding protein 4 |
decreases expression |
ISO |
bleomycetin results in decreased expression of RBP4 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 1:256,806,476...256,813,678
Ensembl chr 1:256,806,472...256,813,711
|
|
G |
Rps4x |
ribosomal protein S4, X-linked |
decreases expression |
ISO |
bleomycetin results in decreased expression of RPS4X mRNA |
CTD |
PMID:21040473 |
|
NCBI chr X:72,074,108...72,078,551
Ensembl chr X:72,074,108...72,078,551 Ensembl chr 4:72,074,108...72,078,551
|
|
G |
Rsl1d1 |
ribosomal L1 domain containing 1 |
increases expression |
ISO |
bleomycetin results in increased expression of RSL1D1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr10:4,375,329...4,387,195
Ensembl chr10:4,356,915...4,390,030
|
|
G |
Ruvbl1 |
RuvB-like AAA ATPase 1 |
increases expression |
ISO |
bleomycetin results in increased expression of RUVBL1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 4:120,411,917...120,447,458
Ensembl chr 4:120,411,991...120,447,455
|
|
G |
Scnn1a |
sodium channel epithelial 1 subunit alpha |
decreases expression |
ISO |
bleomycetin results in decreased expression of SCNN1A mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 4:157,834,339...157,860,472
Ensembl chr 4:157,836,912...157,860,049
|
|
G |
Sdc4 |
syndecan 4 |
increases expression |
ISO |
bleomycetin results in increased expression of SDC4 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 3:160,872,503...160,891,190
Ensembl chr 3:160,872,503...160,891,190
|
|
G |
Sfpq |
splicing factor proline and glutamine rich |
increases expression |
ISO |
bleomycetin results in increased expression of SFPQ mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 5:145,079,803...145,088,517
Ensembl chr 5:145,079,803...145,088,498
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
increases expression |
ISO |
bleomycetin results in increased expression of SGK1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 1:24,185,451...24,302,309
Ensembl chr 1:24,185,435...24,302,298
|
|
G |
Sltm |
SAFB-like, transcription modulator |
decreases expression |
ISO |
bleomycetin results in decreased expression of SLTM mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 8:76,977,698...77,022,847
Ensembl chr 8:76,977,822...77,022,837
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
ISO |
bleomycetin results in increased expression of SOCS3 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
ISO |
bleomycetin results in increased expression of SRXN1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 3:147,608,850...147,614,410
Ensembl chr 3:147,609,095...147,632,801
|
|
G |
Tcp1 |
t-complex 1 |
decreases expression |
ISO |
bleomycetin results in decreased expression of TCP1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 1:48,025,664...48,033,343
Ensembl chr 1:48,025,663...48,033,396
|
|
G |
Tma7 |
translation machinery associated 7 homolog |
decreases expression |
ISO |
bleomycetin results in decreased expression of TMA7 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 8:117,815,725...117,820,422
Ensembl chr 8:117,815,725...117,820,413
|
|
G |
Tmem230 |
transmembrane protein 230 |
increases expression |
ISO |
bleomycetin results in increased expression of TMEM230 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 3:124,870,867...124,879,274
Ensembl chr 3:124,870,869...124,879,216
|
|
G |
Tpm4 |
tropomyosin 4 |
increases expression |
ISO |
bleomycetin results in increased expression of TPM4 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr16:19,385,810...19,399,851
Ensembl chr16:19,385,736...19,399,903
|
|
G |
Tsc22d1 |
TSC22 domain family, member 1 |
increases expression |
ISO |
bleomycetin results in increased expression of TSC22D1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr15:58,554,358...58,658,156
Ensembl chr15:58,554,374...58,658,153
|
|
G |
Upp1 |
uridine phosphorylase 1 |
decreases expression |
ISO |
bleomycetin results in decreased expression of UPP1 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr14:89,314,234...89,334,060
Ensembl chr14:89,314,176...89,334,276
|
|
G |
Usp37 |
ubiquitin specific peptidase 37 |
decreases expression |
ISO |
bleomycetin results in decreased expression of USP37 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 9:81,717,626...81,818,421
Ensembl chr 9:81,716,876...81,772,851
|
|
G |
Uxt |
ubiquitously-expressed, prefoldin-like chaperone |
decreases expression |
ISO |
bleomycetin results in decreased expression of UXT mRNA |
CTD |
PMID:21040473 |
|
NCBI chr X:1,275,402...1,287,781
Ensembl chr X:1,275,612...1,287,512
|
|
G |
Zfp541 |
zinc finger protein 541 |
decreases expression |
ISO |
bleomycetin results in decreased expression of ZNF541 mRNA |
CTD |
PMID:21040473 |
|
NCBI chr 1:77,957,188...77,993,816
Ensembl chr 1:77,967,755...77,992,027
|
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein] which co-treated with deoxynivalenol] promotes the reaction [[ELAVL1 protein binds to ATF3 3' UTR] which results in increased stability of ATF3 mRNA]; [[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein] promotes the reaction [[ELAVL1 protein binds to ATF3 3' UTR] which results in increased stability of ATF3 mRNA]; [[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of ATF3 mRNA; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [15-acetyldeoxynivalenol results in increased expression of ATF3 mRNA]; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of ATF3 mRNA]; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of ATF3 mRNA]; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which results in increased stability of ATF3 mRNA; ATF3 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the phosphorylation of RELA protein] |
CTD |
PMID:22003189 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
B2m |
beta-2 microglobulin |
increases activity |
ISO |
Acetylmuramyl-Alanyl-Isoglutamine analog results in increased activity of B2M protein |
CTD |
PMID:15905553 |
|
NCBI chr 3:114,087,287...114,093,311
Ensembl chr 3:114,087,287...114,093,309
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions increases expression |
ISO |
[2,3-bis(palmitoyloxy)-2-propyl-N-palmitoyl-cysteinyl-seryl-seryl-asparaginyl-alanine co-treated with Acetylmuramyl-Alanyl-Isoglutamine] results in increased expression of CD40 protein; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine] results in increased expression of CD40 protein; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipopolysaccharides] results in increased expression of CD40 protein Acetylmuramyl-Alanyl-Isoglutamine results in increased expression of CD40 protein |
CTD |
PMID:16299289 |
|
NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions increases expression |
ISO |
[Acetylmuramyl-Alanyl-Isoglutamine co-treated with heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine] results in increased expression of CD80 protein; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipopolysaccharides] results in increased expression of CD80 protein Acetylmuramyl-Alanyl-Isoglutamine results in increased expression of CD80 protein |
CTD |
PMID:16299289 |
|
NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
|
|
G |
Cd83 |
CD83 molecule |
multiple interactions increases expression |
ISO |
[Acetylmuramyl-Alanyl-Isoglutamine co-treated with heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine] results in increased expression of CD83 protein; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipopolysaccharides] results in increased expression of CD83 protein Acetylmuramyl-Alanyl-Isoglutamine results in increased expression of CD83 protein |
CTD |
PMID:16299289 |
|
NCBI chr17:24,416,651...24,435,790
Ensembl chr17:24,416,651...24,435,790
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions increases expression |
ISO |
[Acetylmuramyl-Alanyl-Isoglutamine co-treated with heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine] results in increased expression of CD86 protein; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipopolysaccharides] results in increased expression of CD86 protein Acetylmuramyl-Alanyl-Isoglutamine results in increased expression of CD86 protein |
CTD |
PMID:16299289 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of CXCL1 mRNA]; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of CXCL1 mRNA]; ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA] |
CTD |
PMID:22003189 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of CXCL1 mRNA]; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of CXCL1 mRNA]; ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA] |
CTD |
PMID:22003189 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Egf |
epidermal growth factor |
increases expression |
ISO |
muramyl dipeptide increases expression of Egf mRNA in splenocytes |
RGD |
PMID:30615126 |
RGD:39938959 |
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
multiple interactions |
ISO |
[[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein] which co-treated with deoxynivalenol] promotes the reaction [[ELAVL1 protein binds to ATF3 3' UTR] which results in increased stability of ATF3 mRNA]; [[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein] promotes the reaction [[ELAVL1 protein binds to ATF3 3' UTR] which results in increased stability of ATF3 mRNA]; [[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the localization of ELAVL1 protein; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein; ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA]; ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL8 mRNA] |
CTD |
PMID:22003189 |
|
NCBI chr12:2,461,502...2,502,432
Ensembl chr12:2,461,502...2,502,432
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
increases expression |
ISO |
muramyl dipeptide increases expression of Ido1 mRNA in peritoneal macrophages and splenocytes |
RGD |
PMID:30615126 |
RGD:39938959 |
NCBI chr16:72,216,326...72,228,098
Ensembl chr16:72,216,326...72,228,098
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipid A] results in increased expression of IFNG mRNA; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipid A] results in increased expression of IFNG protein; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of [IL12B protein binds to IL23A protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of IL12B protein; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with resiquimod co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with resiquimod co-treated with IFNG protein] results in increased expression of IL12A mRNA; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with resiquimod co-treated with IFNG protein] results in increased expression of IL12B mRNA; resiquimod promotes the reaction [[Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]]; resiquimod promotes the reaction [[Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of IL12B protein] Acetylmuramyl-Alanyl-Isoglutamine promotes the reaction [Lipopolysaccharides results in increased expression of IFNG protein] |
CTD |
PMID:16299289 PMID:18490488 PMID:19897531 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
[Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipid A] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipid A] results in increased expression of IL12A mRNA; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipopolysaccharides] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with resiquimod co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with resiquimod co-treated with IFNG protein] results in increased expression of IL12A mRNA; resiquimod promotes the reaction [[Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:16299289 PMID:18490488 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il12b |
interleukin 12B |
increases secretion multiple interactions |
ISO |
Acetylmuramyl-Alanyl-Isoglutamine analog results in increased secretion of IL12B protein Acetylmuramyl-Alanyl-Isoglutamine promotes the reaction [Lipopolysaccharides results in increased expression of IL12B protein] [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipid A] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipid A] results in increased expression of IL12B mRNA; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipopolysaccharides] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of [IL12B protein binds to IL23A protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of IL12B protein; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with resiquimod co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with resiquimod co-treated with IFNG protein] results in increased expression of IL12B mRNA; resiquimod promotes the reaction [[Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]]; resiquimod promotes the reaction [[Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of IL12B protein] |
CTD |
PMID:15905553 PMID:16299289 PMID:18490488 PMID:19897531 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il15 |
interleukin 15 |
multiple interactions |
ISO |
[Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipid A] results in increased expression of IL15 mRNA |
CTD |
PMID:16299289 |
|
NCBI chr19:23,542,606...23,624,366
Ensembl chr19:23,542,889...23,554,594
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
[Pamidronate results in increased susceptibility to Acetylmuramyl-Alanyl-Isoglutamine] which results in increased secretion of IL18 protein |
CTD |
PMID:21282739 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1a |
interleukin 1 alpha |
increases response to substance |
ISO |
IL1A protein results in increased susceptibility to Acetylmuramyl-Alanyl-Isoglutamine |
CTD |
PMID:19897531 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
affects expression multiple interactions increases secretion increases response to substance |
ISO |
Acetylmuramyl-Alanyl-Isoglutamine affects the expression of IL1B protein [Pamidronate co-treated with Acetylmuramyl-Alanyl-Isoglutamine] results in increased secretion of IL1B protein; geraniol inhibits the reaction [[Pamidronate co-treated with Acetylmuramyl-Alanyl-Isoglutamine] results in increased secretion of IL1B protein] Acetylmuramyl-Alanyl-Isoglutamine results in increased secretion of IL1B protein [Acetylmuramyl-Alanyl-Isoglutamine co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form IL1B protein results in increased susceptibility to Acetylmuramyl-Alanyl-Isoglutamine |
CTD |
PMID:17404311 PMID:19897531 PMID:21282739 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
[Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of [IL12B protein binds to IL23A protein] |
CTD |
PMID:18490488 |
|
NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
|
|
G |
Il6 |
interleukin 6 |
increases secretion |
ISO |
Acetylmuramyl-Alanyl-Isoglutamine analog results in increased secretion of IL6 protein |
CTD |
PMID:15905553 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
increases response to substance |
ISO |
MYD88 protein results in increased susceptibility to Acetylmuramyl-Alanyl-Isoglutamine analog |
CTD |
PMID:15905553 |
|
NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases phosphorylation |
ISO |
Curcumin inhibits the reaction [Acetylmuramyl-Alanyl-Isoglutamine results in increased phosphorylation of NFKBIA protein]; parthenolide inhibits the reaction [Acetylmuramyl-Alanyl-Isoglutamine results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:18413660 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nod2 |
nucleotide-binding oligomerization domain containing 2 |
multiple interactions increases expression |
ISO |
[[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein] which co-treated with deoxynivalenol] promotes the reaction [[ELAVL1 protein binds to ATF3 3' UTR] which results in increased stability of ATF3 mRNA]; [[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein] promotes the reaction [[ELAVL1 protein binds to ATF3 3' UTR] which results in increased stability of ATF3 mRNA]; [[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the localization of ELAVL1 protein; [[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the phosphorylation of RELA protein; [[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of ATF3 mRNA; [[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA; [[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL8 mRNA; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [15-acetyldeoxynivalenol results in increased expression of ATF3 mRNA]; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of ATF3 mRNA]; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of CXCL1 mRNA]; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of CXCL8 mRNA]; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of ATF3 mRNA]; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of CXCL1 mRNA]; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of CXCL8 mRNA]; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which results in increased stability of ATF3 mRNA; Acetylmuramyl-Alanyl-Isoglutamine binds to and affects the activity of NOD2 protein; Acetylmuramyl-Alanyl-Isoglutamine promotes the reaction [NOD2 protein binds to NOD2 protein]; ATF3 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the phosphorylation of RELA protein]; Curcumin inhibits the reaction [Acetylmuramyl-Alanyl-Isoglutamine promotes the reaction [NOD2 protein binds to NOD2 protein]]; ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA]; ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL8 mRNA] Acetylmuramyl-Alanyl-Isoglutamine results in increased expression of NOD2 protein |
CTD |
PMID:18413660 PMID:22003189 PMID:28450277 |
|
NCBI chr19:19,342,061...19,389,366
Ensembl chr19:19,332,594...19,377,492
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases activity |
ISO |
[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the phosphorylation of RELA protein; Acetylmuramyl-Alanyl-Isoglutamine results in increased phosphorylation of and affects the localization of RELA protein; ATF3 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the phosphorylation of RELA protein]; Curcumin inhibits the reaction [Acetylmuramyl-Alanyl-Isoglutamine results in increased activity of RELA protein]; Curcumin inhibits the reaction [Acetylmuramyl-Alanyl-Isoglutamine results in increased phosphorylation of and affects the localization of RELA protein]; helenalin inhibits the reaction [Acetylmuramyl-Alanyl-Isoglutamine results in increased activity of RELA protein]; parthenolide inhibits the reaction [Acetylmuramyl-Alanyl-Isoglutamine results in increased activity of RELA protein]; parthenolide inhibits the reaction [Acetylmuramyl-Alanyl-Isoglutamine results in increased phosphorylation of RELA protein] |
CTD |
PMID:18413660 PMID:22003189 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
decreases expression |
ISO |
Acetylmuramyl-Alanyl-Isoglutamine results in decreased expression of SOCS1 protein |
CTD |
PMID:19897531 |
|
NCBI chr10:4,956,795...4,958,472
Ensembl chr10:4,957,326...4,958,461
|
|
G |
Tlr2 |
toll-like receptor 2 |
increases activity increases response to substance |
ISO |
Acetylmuramyl-Alanyl-Isoglutamine analog results in increased activity of TLR2 protein TLR2 protein results in increased susceptibility to Acetylmuramyl-Alanyl-Isoglutamine analog |
CTD |
PMID:15905553 |
|
NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases activity increases response to substance |
ISO |
Acetylmuramyl-Alanyl-Isoglutamine analog results in increased activity of TLR4 protein TLR4 protein results in increased susceptibility to Acetylmuramyl-Alanyl-Isoglutamine analog |
CTD |
PMID:15905553 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
increases secretion increases response to substance multiple interactions |
ISO |
Acetylmuramyl-Alanyl-Isoglutamine analog results in increased secretion of TNF protein TNF protein results in increased susceptibility to Acetylmuramyl-Alanyl-Isoglutamine Acetylmuramyl-Alanyl-Isoglutamine promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Plant Extracts inhibits the reaction [Acetylmuramyl-Alanyl-Isoglutamine results in increased expression of TNF protein] |
CTD |
PMID:15905553 PMID:17568627 PMID:19897531 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Ctsl |
cathepsin L |
decreases activity |
ISO |
Teicoplanin results in decreased activity of CTSL protein |
CTD |
PMID:26953343 |
|
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
EXP |
Teicoplanin results in decreased activity of PGD protein |
CTD |
PMID:15558954 |
|
NCBI chr 5:165,966,128...165,982,327
|
|
|
G |
A2m |
alpha-2-macroglobulin |
increases expression |
EXP |
Vancomycin results in increased expression of A2M mRNA |
CTD |
PMID:18289764 |
|
NCBI chr 4:154,309,426...154,359,138
Ensembl chr 4:154,309,426...154,359,137
|
|
G |
Aadac |
arylacetamide deacetylase |
increases expression |
ISO |
Vancomycin results in increased expression of AADAC mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 2:150,146,234...150,157,480
Ensembl chr 2:150,146,234...150,157,480
|
|
G |
Aadat |
aminoadipate aminotransferase |
increases expression |
ISO |
Vancomycin results in increased expression of AADAT mRNA |
CTD |
PMID:18930951 |
|
NCBI chr16:32,832,001...32,868,680
Ensembl chr16:32,832,061...32,868,702
|
|
G |
Aass |
aminoadipate-semialdehyde synthase |
increases expression |
ISO |
Vancomycin results in increased expression of AASS mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 4:50,152,005...50,208,935
Ensembl chr 4:50,152,452...50,200,328
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
increases expression |
ISO |
Vancomycin results in increased expression of ABAT mRNA |
CTD |
PMID:18930951 |
|
NCBI chr10:7,093,406...7,200,439
Ensembl chr10:7,093,405...7,200,499
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
Vancomycin results in decreased expression of ABCA1 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abca13 |
ATP binding cassette subfamily A member 13 |
increases expression |
ISO |
Vancomycin results in increased expression of ABCA13 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr14:89,384,512...89,876,748
Ensembl chr14:89,384,512...89,714,917
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
[Vancomycin co-treated with Imipenem] results in increased expression of ABCB11 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases expression increases expression |
ISO EXP |
[Vancomycin co-treated with Imipenem] results in decreased expression of ABCB1A mRNA JBP 485 inhibits the reaction [Vancomycin results in decreased expression of ABCB1A mRNA]; JBP 485 inhibits the reaction [Vancomycin results in decreased expression of ABCB1A protein] Vancomycin results in decreased expression of ABCB1A mRNA; Vancomycin results in decreased expression of ABCB1A protein Cilastatin inhibits the reaction [Vancomycin results in decreased expression of and affects the localization of ABCB1 protein]; Vancomycin results in decreased expression of and affects the localization of ABCB1 protein Vancomycin results in increased expression of ABCB1A mRNA |
CTD |
PMID:18930951 PMID:24657338 PMID:28549670 PMID:29964132 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
increases expression |
ISO |
Vancomycin results in increased expression of ABCB1B mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions decreases expression |
ISO EXP |
[Vancomycin co-treated with Imipenem] affects the expression of ABCC2 mRNA Vancomycin results in decreased expression of ABCC2 mRNA; Vancomycin results in decreased expression of ABCC2 protein JBP 485 inhibits the reaction [Vancomycin results in decreased expression of ABCC2 mRNA]; JBP 485 inhibits the reaction [Vancomycin results in decreased expression of ABCC2 protein] |
CTD |
PMID:24657338 PMID:29964132 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[Vancomycin co-treated with Imipenem] results in decreased expression of ABCC3 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcd4 |
ATP binding cassette subfamily D member 4 |
increases expression |
ISO |
Vancomycin results in increased expression of ABCD4 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 6:108,315,026...108,329,550
Ensembl chr 6:108,315,035...108,329,464
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
[Vancomycin co-treated with Imipenem] affects the expression of ABCG5 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 6:7,935,771...7,961,207
Ensembl chr 6:7,935,771...7,961,207
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
multiple interactions |
ISO |
[Vancomycin co-treated with Imipenem] affects the expression of ABCG8 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 6:7,961,413...7,980,708
Ensembl chr 6:7,961,413...7,980,708
|
|
G |
Abhd1 |
abhydrolase domain containing 1 |
increases expression |
ISO |
Vancomycin results in increased expression of ABHD1 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 6:26,787,807...26,792,795
Ensembl chr 6:26,784,058...26,792,808
|
|
G |
Abhd14a |
abhydrolase domain containing 14A |
increases expression |
ISO |
Vancomycin results in increased expression of ABHD14A mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 8:115,141,575...115,151,222
Ensembl chr 8:115,141,539...115,149,527
|
|
G |
Abhd3 |
abhydrolase domain containing 3, phospholipase |
increases expression |
ISO |
Vancomycin results in increased expression of ABHD3 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr18:1,892,413...1,946,840
Ensembl chr18:1,892,413...1,946,840
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
increases expression |
ISO |
Vancomycin results in increased expression of ACAA2 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr18:70,733,872...70,762,395
Ensembl chr18:70,733,872...70,762,395
|
|
G |
Acad10 |
acyl-CoA dehydrogenase family, member 10 |
increases expression |
ISO |
Vancomycin results in increased expression of ACAD10 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr12:40,417,918...40,460,562
Ensembl chr12:40,417,944...40,460,561
|
|
G |
Acad9 |
acyl-CoA dehydrogenase family, member 9 |
increases expression |
ISO |
Vancomycin results in increased expression of ACAD9 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 2:122,782,051...122,806,166
Ensembl chr 2:122,782,060...122,805,768
|
|
G |
Acadsb |
acyl-CoA dehydrogenase, short/branched chain |
increases expression |
ISO |
Vancomycin results in increased expression of ACADSB mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 1:201,981,362...202,022,771
Ensembl chr 1:201,981,357...202,021,008
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
increases expression |
ISO |
Vancomycin results in increased expression of ACAT1 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 8:58,166,990...58,195,884
Ensembl chr 8:58,166,990...58,195,884
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACAT2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:47,972,399...47,992,654
Ensembl chr 1:47,972,399...47,992,653
|
|
G |
Acat2l1 |
acetyl-CoA acetyltransferase 2-like 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACAT2L1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:48,008,574...48,025,730
Ensembl chr 1:47,996,521...48,026,268
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACE2 protein |
CTD |
PMID:30545405 |
|
NCBI chr X:32,050,734...32,095,860
Ensembl chr X:32,049,931...32,096,016
|
|
G |
Ache |
acetylcholinesterase |
affects activity multiple interactions |
EXP |
Vancomycin affects the activity of ACHE protein zingerone affects the reaction [Vancomycin affects the activity of ACHE protein] |
CTD |
PMID:31454121 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Acot3 |
acyl-CoA thioesterase 3 |
increases expression |
ISO |
Vancomycin results in increased expression of ACOT3 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 6:107,531,508...107,537,446
Ensembl chr 6:107,531,528...107,536,789
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
increases expression |
ISO |
Vancomycin results in increased expression of ACOT4 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 6:107,517,668...107,522,952
Ensembl chr 6:107,517,668...107,522,952
|
|
G |
Acot9 |
acyl-CoA thioesterase 9 |
decreases expression |
ISO |
Vancomycin results in decreased expression of ACOT9 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr X:43,543,069...43,592,200
Ensembl chr X:43,543,070...43,592,200
|
|
G |
Acox2 |
acyl-CoA oxidase 2 |
increases expression |
ISO |
Vancomycin results in increased expression of ACOX2 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr15:18,449,304...18,481,472
Ensembl chr15:18,451,144...18,481,470
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
increases expression |
ISO |
Vancomycin results in increased expression of ACSL1 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr16:48,937,456...49,003,898
Ensembl chr16:48,937,456...49,003,246
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
decreases expression |
ISO |
Vancomycin results in decreased expression of ACSL4 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr X:113,596,247...113,660,024
Ensembl chr X:113,596,239...113,659,944
|
|
G |
Acsm1 |
acyl-CoA synthetase medium-chain family member 1 |
increases expression |
ISO |
Vancomycin results in increased expression of ACSM1 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 1:189,359,374...189,395,277
Ensembl chr 1:189,289,957...189,395,276
|
|
G |
Acsm2 |
acyl-CoA synthetase medium-chain family member 2 |
increases expression |
ISO |
Vancomycin results in increased expression of ACSM2 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 1:189,289,957...189,329,007
Ensembl chr 1:189,289,957...189,395,276
|
|
G |
Acsm3 |
acyl-CoA synthetase medium-chain family member 3 |
increases expression |
ISO |
Vancomycin results in increased expression of ACSM3 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 1:189,514,504...189,541,233
Ensembl chr 1:189,514,553...189,541,224
|
|
G |
Acss1 |
acyl-CoA synthetase short-chain family member 1 |
increases expression |
ISO |
Vancomycin results in increased expression of ACSS1 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 3:146,420,346...146,470,293
Ensembl chr 3:146,420,346...146,470,293
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
increases expression |
ISO |
Vancomycin results in increased expression of ACSS2 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 3:151,032,925...151,075,856
Ensembl chr 3:151,032,952...151,075,856
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
ISO |
Vancomycin results in decreased expression of ACTA2 mRNA |
CTD |
PMID:18930951 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Actb |
actin, beta |
increases expression |
ISO |
Vancomycin results in increased expression of ACTB mRNA |
CTD |
PMID:18930951 |
|
NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
|
|
G |
Actn1 |
actinin, alpha 1 |
decreases expression |
ISO |
Vancomycin results in decreased expression of ACTN1 mRNA |
| |